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Despite the fact that Beta-Endorphin (B-EP) has been shown to 
cause hyperglycemia at rest, it is not known if it influences glucose 
homeostasis and the glucoregulatory hormones during exercise. In an 
attempt to clarify the role of B-EP in glucose regulation and hormonal 
responses to prolonged dynamic exercise, 72 untrained, male 
Sprague-Dawley rats were assigned to one of three treatments: a) a 
control group infused with normal saline, b) a group infused with rat 
synthetic B-EP (0.05 mg*kg~l*h~l after a 0.05 mg/ kg bolus), and c) 
a group infused with naloxone (0.4 mg*kg~l*h~l after a 0.8 mg*kg~l 
bolus). All animals were familiarized with treadmill running for 4 
days. On the fifth day they were catheterized in the jugular vein, and 
allowed 4 days recovery period. All recovered catheterized animals 
went through a second familiarization running period for 4 days. 
Finally, animals in each group were infused and killed either at 0 
time or after 60, 90 and 120 minutes of running. Mixed venous 
samples were collected and subsequently analyzed for plasma 
glucose, lactate, insulin, C-peptide (C-P), glucagon, and B-EP. 
A 3*4 ANOVA (treatment by time) revealed that plasma glucose 
was maintained at significantly higher levels in the B-EP group 
compared to the other two at 60 (142.2 ± 7.7 mg*dl"l vs 110.8 ± 6.4 
mg*dl"l in the control group and vs 119.2 ± 9.2 mg*dl~l in the 
naloxone group) and 90 minutes (99.8 + 6.8 mg*dl~l vs 81.7 + 4.9 
mg*dl"l in the control group and vs 84.1 + 5.9 mg*dl~l in the 
naloxone group) of exercise. These differences were accompanied 
with changes in the responses of the pancreatic hormones between 
groups. Plasma insulin was significantly lower in the B-EP group at 
60 min., while plasma C-P was significantly reduced in the B-EP 
group compared to the control and naloxone groups at 60 and 90 
minutes of exercise. The C-P to insulin molar ratio declined 
significantly in the B-EP group compared to the other groups after 90 
minutes of exercise, suggesting reduced insulin clearance in that 
group. Plasma glucagon increased significantly in the B-EP group 
compared to the other two groups at 60 and 90 minutes of exercise. 
Plasma lactate was significantly elevated in the B-EP group compared 
to the other two treatments at 60, 90 and 120 minutes of exercise. 
Plasma B-EP was significantly increased in the B-EP group as 
compared to the other groups at all times. 
These data suggest that B-EP could act to prevent the decline in 
plasma glucose levels during exercise. It appears that this effect may 
be secondary to B-EP influence on the pancreatic hormones, insulin 
and glucagon, since a significant decline of insulin and increase of 
glucagon was observed with B-EP infusion, especially at 60 and 90 
minutes of exercise. 
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CHAPTER I 
INTRODUCTION 
Statement of the Problem 
Maintenance of plasma glucose concentration is critical to 
survival because it is the predominant metabolic fuel utilized by the 
central nervous system and red blood cells under most conditions. 
The central nervous system and red blood cells can not synthesize or 
store adequate amounts of glucose. Erythrocytes require steady 
supply of glucose since they lack mitochondria and therefore can not 
utilize fatty acid fuels. Skeletal muscle and cardiac muscle use fatty 
acids but they require glucose especially during strenuous activity. 
Cells can take up glucose by facilitated diffusion and active transport 
which means that blood glucose concentrations need to be 
maintained at a certain level. Therefore, due to the crucial role of 
glucose for life its blood concentration is normally kept within a 
relatively narrow range, roughly 60 to 150 mg*dl~l, despite wide 
variations in glucose influx and efflux (Cryer, 1989). 
Situations where blood glucose fluctuates from that narrow 
range for prolonged periods of time could be proved to be 
detrimental. Hypoglycemia can cause profound brain dysfunction, 
and prolonged, severe hypoglycemia causes brain death. Other 
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deleterious effects of sustained low blood glucose concentrations 
include loss of motivation, headache, disturbances in sensory 
perception, loss of coordination, sweating, involuntary tremors that 
progress to muscle spasms, convulsions, loss of consciousness, and 
finally death. However, it is also important that the blood glucose 
levels not rise too high for several reasons. Glucose exerts a large 
amount of osmotic pressure in the extracellular fluid. If the glucose 
concentration rises to excessive values, this can cause considerable 
cellular dehydration. Excessively high blood glucose concentration 
causes loss of glucose in the urine. This results in osmotic diuresis by 
the kidneys, which can deplete the body of its fluids and electrolytes. 
Blood glucose concentration is kept within a narrow and normal 
range due to fine control by insulin and the counterregulatory 
hormones. Insulin lowers plasma glucose and the counterregulatory 
hormones increase glucose levels when it is low. 
When glucose is elevated (higher than 150 mg*dl~l), insulin 
release is increased resulting in glucose storage (glycogenesis) and 
utilization by different tissues such as liver, muscle, and adipose 
(Cherrington et al., 1981). At the same time the counterregulatory 
hormones, namely, glucagon, catecholamines (epinephrine and 
norepinephrine), Cortisol, and growth hormone are inhibited. When 
plasma glucose falls to subnormal levels, insulin release is inhibited 
and the counteregulatory hormones are stimulated. This results in 
glucose production either through glycogenolysis or gluconeogenesis 
and inhibition of glucose uptake by the peripheral tissues (Deibert et 
al., 1980). 
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There are some interelationships between these hormones such 
as inhibition of insulin release and stimulation of glucagon secretion 
by catecholamines (Gray et al., 1980). These hormonal changes and 
metabolic shifts are brought about by a glucostatic mechanism that 
detects glucose changes both centrally and peripherally which tries 
to maintain glucose homeostasis. 
Fat metabolism is also under hormonal control maintaining a 
balance between lipogenesis and lipolysis with insulin favoring the 
former and catecholamines, growth hormone, glucagon and Cortisol 
supporting the latter ( Issekutz, 1975; Jarhult & Hoist, 1979 ). 
Increased utilization of lipids ( Owen et al., 1967 ) and occasionally 
protein ( Cryer, 1989 ) for energy production helps to spare glucose. 
Exercise is a stressor where a significant metabolic acceleration 
is achieved due to the special metabolic demands imposed on the 
working muscular system. Carbohydrates and fat are the two major 
energy fuels used during exercise, depending on the intensity and 
duration of the work performed (Vranic et al., 1979). Carbohydrate 
utilization predominates but fats can contribute a significant supply 
of energy at lighter intensities and longer durations of exercise. 
Carbohydrate utilization is achieved at higher intensities and at the 
initiation of exercise (Vranic et al., 1979). During long-term work as 
in distance running, glucose utilization exceeds its production 
resulting in hypoglycemia after 90 to 120 minutes of exercise. Under 
these conditions glycogen stores and carbohydrate availability in 
general can limit performance (Fox, 1989). With aerobic exercise 
insulin is inhibited and glucagon and catecholamines (epinephrine 
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and norepinephrine) are stimulated trying to maintain plasma 
glucose levels from falling (Gollnick et al., 1974). Fat utilization 
through lipolysis and some times ketogenesis can aid to spare glucose 
(Gollnick et al., 1974). Exercise stimulates mechanisms that help to 
regulate glucose homeostasis and fat metabolism. 
Beta-Endorphin (B-EP) has been suggested to play a role in the 
regulation of glucose homeostasis in stress situations (Giugliano, 
1988). B-EP is a neurohormone peptide with potent opioid action. It 
is secreted by the pituitary and hypothalamus. The demonstration 
that B-EP is widely distributed in sites involved in glucose 
homeostasis, including the central and peripheral divisions of the 
autonomic nervous system, pancreas, gut, and hypothalamo-pituitary 
axis, has led to the suggestion that it may participate in the 
regulation of glucose homeostasis and fat metabolism (Krieger, 1980, 
1983). 
It has been indicated that B-EP release, either centrally or 
peripherally, was potentiated by induced hypoglycemia (Kjaer et al., 
1993; Nakao et al., 1979) and negative energy balance situations 
such as starvation (Walberg- Rankin et al., 1992; Kuldeep et al., 
1985). A negative correlation (- 0.91) was obtained between plasma 
glucose levels and plasma B-EP during insulin-induced hypoglycemia 
(Kjaer et al., 1993). These findings were accompanied by 
observations that in most cases, B-EP infusion in vivo or in vitro 
results in hyperglycemia (Reid et al., 1981; Feldman et al., 1983; 
Matsumura et al., 1984). Eventhough it has not been confirmed by all 
studies, data suggests that this hyperglycemic effect of B-EP could 
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enhance glycogenolysis (Matsumura et al., 1984) or gluconeogenesis 
(Matsumura et al., 1984; Dave et al., 1985) and inhibit glucose 
clearance (Radosevich et al., 1989). However, these observations 
were not consistent. 
B-EP and other endogenous opioids appear to have a potent 
lipolytic activity in vitro (Richter et al., 1987, Vettor et al., 1993). 
Results from animal studies have also suggested a lipolytic effect of 
B-EP (Grag et al., 1977; Schwandt et al., 1979), but it is still 
uncertain if this occurs in humans. 
Paolisso et al (1987), suggested that the induced metabolic 
changes induced by B-EP are secondary to its effect on hormones 
such as insulin, glucagon and possibly catecholamines. The action of 
B-EP on glucose homeostasis and on the regulation of lipid 
metabolism might be indirect rather than direct. Despite the fact that 
in vitro and in vivo studies agree that B-EP stimulates glucagon 
release from the pancreas (Reid et al., 1981; Feldman et al., 1983; Ipp 
et al., 1980), a great deal of controversy exists on the effects of B-EP 
on insulin and catecholamine release. Previous experimental findings 
point towards both stimulation (Reid et al., 1981; Feldman et al., 
1983; Van Loon et al., 1981) and inhibition (Rudman et al., 1983; 
Matsumura et al., 1984; Mannelli et al., 1984; Farrell et al., 1991) of 
insulin and catecholamines. 
It was reported that B-EP is increased by exercise (Blake et al., 
1984; Goldfarb et al., 1987, 1991). Eventhough some investigators 
attributed this elevation to pain and mood regulation induced by 
exercise (Arentz et al., 1986; Olausson et al., 1986), few efforts were 
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made to explore the metabolic actions of B-EP during exercise and its 
role in the regulation of plasma glucose and lipolysis. There is a need 
to investigate if B-EP acts as a part of the metabolic mechanism 
during exercise since regulation of glucose homeostasis is critical not 
only for sports performance, but also for optimal health. In addition, 
if B-EP plays a role in substrate utilization during exercise, it should 
be determined if this action is direct or indirect. The aim of this 
study was to determine if B-EP affects glucose homeostasis and 
evaluate its effects on the major glucoregulatory hormones, namely 
insulin and glucagon. 
Purpose 
The purpose of this study was to evaluate the metabolic effects 
of B-EP during an acute bout of endurance aerobic exercise. This 
study attempted to determine how B-EP and naloxone, a drug that 
inhibits B-EP binding to its opioid receptors, affect plasma glucose 
during an acute bout of aerobic exercise. In addition, B-EP effects on 
the counterregulatory hormones involved in glucose homeostasis 
during exercise, namely insulin and glucagon were determined. 
Hypotheses 
The null form of hypothesis statement was chosen since 
previous research in the related literature is controversial and the 
metabolic effects of B-EP during exercise have not been investigated 
in depth. The researcher hypothesized that upon comparison of the 
three treatment groups: 
1. There will be no significant differences among the three 
groups in plasma glucose levels during the two-hour running period. 
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2. There will be no significant differences among the three 
groups in plasma levels of C-peptide, insulin and glucagon during the 
two-hour running period. 
3. There will be no significant differences among the three 
groups in plasma lactate levels during the two-hour running period. 
4. There will be no significant differences among the three 
groups in plasma B-EP levels during the two-hour running period. 
Basic Assumptions 
All rats underewent surgery under anesthesia for intravenous 
catheter placement. The animal post-surgery recovery was 
completed three to five days prior to treatment intervention and it 
did not affect the treatment effectiveness. All rats went through an 
eight day familiarization period on the treadmill to insure that the 
rats were able to run for 120 minutes without problems. It is 
assumed that intravenous administration of the drugs (B-EP and 
naloxone) and placebo did not cause any undesired side effects to 
the animals so that their physiological responses and running 
performance were not impaired. Finally, it was assumed that the 
drug dosages were adequate in order to elicit the expected responses. 
Limitations of the Study 
Subjects of this study were untrained male Spraque-Dawley rats. 
The exercise protocol used involved a two-hour endurance 
running activity of moderate intensity. Generalizing the findings to 
other exercise modes, intensities and durations may not be 
appropriate. 
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Possible changes obtained due to drug manipulation does not 
indicate that under normal physiological conditions they would occur, 
Insulin and glucagon release were not measured. Their plasma 
concentration was only determined. 
Delimitations of the Study 
1. The subjects were untrained male Spraque-Dawley rats 
weighing 250-300 grams. 
2. The animals ran on the treadmill for up to two hours at 
moderate intensity (at 22 m*min_l). 
3. The B-EP dose was 0.05 mg*hour~l*Kgr~l of body weight. 
4.The dose of the B-EP antagonist, naloxone, was 0.8 
mg*hour_l*Kgr"l of body weight. 
Significance of the study 
Despite the fact that research has shown repeatedly that 
exercise provides a stimulus for B-EP release, the physiological 
significance of this elevation remains unknown at present. Recent 
research implicates B-EP in the regulation of carbohydrate and lipid 
metabolism but the actual mechanisms are not understood. This 
study was a first attempt to assess the effects of B-EP on plasma 
glucose homeostasis during prolonged exercise. In addition, this 
study attempted to determine if B-EP control on substrate 
mobilization during exercise is achieved through actions on the major 
counterregulatory hormones insulin and glucagon. 
Definitions of Term? 
1. Beta-Endorphin (B-EP): A neurohormone peptide with opioid 
functions. B-EP is synthesized by the hypothalamus and pituitary 
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glands as a part of a larger precursor molecule of 
proopiomelanocortin (POMC). After its cleavage as a smaller fragment 
from POMC it acts as a neurotransmitter at nerve synapses in the 
brain or as an endocrine through its release in the peripheral 
circulation. Its action on target tissues is mediated by binding to u-
opioid receptors. 
2. Plasma glucose: A six-carbon molecule existing in the plasma 
and utilized by various tisues mainly for energy purposes. Its 
concentration in the plasma is normally maintained between 60 and 
140 mg*dl"l. 
3. Insulin: A peptide hormone, synthesized in the beta cells of 
the pancreas. It is released in the bloodstream and acts on tissues to 
promote glucose, fat and protein storage. 
4. Glucagon: A peptide hormone released by the alpha cells of 
the pancreas. It is released in the circulation and acts primarily on 
the liver in order to enhance glycogenolysis and glucose release in 
the plasma. 
5. Naloxone: An exogenous drug which binds to the u-opioid 
receptors. Because of this action it can compete and prevent B-EP 
binding on these same receptors. 
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CHAPTER II 
REVIEW OF RELATED LITERATURE 
Mechanisms of Glucoregulation 
Maintenance of plasma glucose concentration is critical to 
survival because plasma glucose is the predominant metabolic fuel 
utilized by the central nervous system and red blood cells. Brief 
hypoglycemia can cause brain dysfunction. Prolonged, severe 
hypoglycemia can cause brain death. Hyperglycemia has deleterious 
effects such as cellular dehydration, osmotic diuresis by the kidneys, 
loss of fluids and electrolytes, and glycosylation of plasma proteins. 
The plasma concentration of glucose is normally kept within an 
optimal range, roughly 60 to 150 mg*dl_l, despite wide variations in 
glucose influx and efflux such as those occuring following meals and 
during exercise (Cryer, 1989). This narrow range of blood glucose 
concentration is preserved due to counterregulatory hormones that 
raise plasma glucose when it falls and decrease glucose when its 
levels are above normal. An outline of how plasma glucose is 
regulated is presented below. 
The liver functions as an important blood glucose buffer system. 
When blood glucose rises to high concentration such as after a meal, 
as much as two thirds of the glucose absorbed by the gut is stored in 
the liver in the form of glycogen. During the subsequent period, 
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when the blood glucose concentration falls, the liver releases glucose 
into the (Sherwin, 1980). 
It is clear that both insulin and glucagon function as the primary 
feedback control endocrines for maintaining normal blood glucose. 
When plasma glucose concentration rises, insulin release increases 
and in turn causes the blood glucose concentration to decrease 
toward normal. Conversely, a decrease in blood glucose stimulates 
glucagon secretion and insulin inhibition. Glucagon functions to 
increase blood glucose. Under normal conditions, the insulin feedback 
mechanism is predominant but diminished glucose intake or 
excessive utilization of glucose, such as during exercise stimulates the 
glucagon mechanism. However, the action of insulin is unique 
because while other counterregulatory hormones can exert action 
similar to that of glucagon only insulin helps to lower blood glucose 
(Cherrington et al., 1981). 
Low blood glucose sensed by the hypothalamus stimulates the 
sympathetic nervous system. Epinephrine secreted by the adrenal 
glands can augment the release of glucose from the liver (Deibert et 
al., 1980). Inhibition of insulin secretion through a-adrenergic 
receptor stimulation by norepinephrine also occurs (Rizza et al., 
1980). Beta-adrenergic stimulation of glucagon also takes place with 
hypoglycemia (Gray et al., 1980). 
Other hormones such as growth hormone and Cortisol, can be 
secreted in response to prolonged hypoglycemia. These hormones 
decrease the rate of glucose utilization by most cells and stimulate 
usage of proteins and fats. Together with glucagon and epinephrine 
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these other hormones help to stimulate the gluconeogenic process 
(Deibert et al., 1980). During fasting, adipocytes can also decrease 
their glucose utilization and satisfy their energy needs from b-
oxidation of fatty acids, helping to spare glucose (Owen et al., 1967). 
In summary, protection of glucose homeostasis is achieved by 
the coordinated action of insulin and the counterregulatory 
endocrines, glucagon, epinephrine growth hormone and Cortisol. 
Backround of Beta-Endorehin. 
A. Biology of B-EP. 
Beta-Endorphin (B-EP), a neurohormone peptide, is classified as 
an endogenous opioid. It is distributed throughout the central 
nervous system, pituitary gland and other peripheral tissues. The 
term opioid is used here to designate a group of endogenous peptides 
that are, to varying degrees, opium- or morphine- like in their 
properties. Hughes et al. (1975), succeeded in isolating the first 
endogenous opioids called methionine- and leucine- enkephalin. In 
the following years opioid peptides have been characterized in 
various areas of the brain (McDowell & Kitchen, 1987). B-EP was 
purified by Li in 1977 and has potent opioid activity. 
Three distinct families of opioid peptides have been identified 
thus far: the enkephalins, the endorphins, and the dynorphins. Each 
family is derived from a distinct precursor polypeptide and has a 
characteristic anatomical distribution. These precursors are now 
designated as proenkephalin (also proenkephalin A), pro­
opiomelanocortin (POMC), and prodynorphin (also proenkephalin B). 
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Figure 1 presents the biologically active peptides that are derived 
from these precursors. 
POMC is an interesting precursor molecule in that it can give rise 
to several biologically active peptides. POMC contains the amino acid 
sequences for melanocyte-stimulating hormone (gamma-MSH), 
adrenocorticotrophin (ACTH), beta-lipotrophin (beta-LPH), B-EP, and 
beta-MSH. Although B-EP contains the sequence for met-enkephalin 
at its amino terminus, it is not converted to this peptide; instead, 
met-enkephalin is derived from the processing of proenkephalin. Of 
these, only B-EP has demonstrated opioid activity, while 
adrenocorticotrophic hormone (ACTH), melanotrophin (MSH), and 
beta-LPH posses non-opioid mediated functions. 
Not all cells that make a given precursor polypeptide store and 
release the same mixture of active opioid (and nonopioid) peptides. 
These differences are thought to arise from variations in the 
posttranslational processing of the precursor polypeptides by 
peptidase enzymes depending on the needs of each individual tissue. 
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Figure 1. Schematic representation of the protein 
precursor structures of the three opioid peptide families. 
Data are taken from Akil et al., Ann. Rev. Neurosci., 7: 223-255, 
1983, and Simons, Endocr. Rev., 9: 200-212, 1988. 
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B. Anatomical localization. 
Beta-Endorphin (B-EP), the most potent known naturally 
occurring analgesic agent, was first isolated and identified as one of a 
series of prohormone fragments present in porcine pituitary 
(Bradbury et al., 1975). It is now known that this opioid peptide 
occurs in a variety of species, ranging from the camel (Li & Chung, 
1976), ostrich (Naude et al., 1980) and salmon (Kawauchi et al., 
1979) to man (Dragon et al., 1977). B-EP is a 31-amino acid peptide 
(its amino acid sequence is shown in figure 2). 
Try-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-
Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Val-Lys-Asn-Ala-His-Lys-Lys-
Gly-Gln 
Figure 2. Beta-Endorphin: A 31 amino-acid sequence. 
Data are taken from Akil et al., Ann. Rev. Neurosc., 7: 223-
255, 1984. 
Beta-Endorphin is accompanied by a group of structurally 
related peptides that are virtually devoid of opioid activity in the 
brain and the pituitary gland (Smyth, 1983). B-EP appears to be 
transformed to its biologically active form, but can be further 
processed to form inactive derivatives. 
In an attempt to understand the physiological role of B-EP, the 
distribution of its active and inactive forms has been studied in 
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various tissues where "immunoreactive B-EP" was known to be 
present. In general B-EP and its derivatives occur in low 
concentration, which makes their isolation and identification difficult. 
However, the peptides can be detected and measured readily with 
the aid of radioimmunoassays (RIA). Specific antibodies for B-EP 
have been used to localize B-EP-immunoreactive peptides by 
immunohistochemical methods (Pelletier et al., 1977; Watson et al., 
1977). The antibodies have been used also for plasma and tissue 
extracts (Guillemin et al., 1977; Holt et al., 1978). When RIAs are 
applied in conjuction with chemical methods for purification of the 
peptides, the different B-EP derivatives can be identified and 
determined. 
Recent research has revealed that the distribution of peptides 
from POMC is relatively large. Their location within the central 
nervous system includes the arcuate nucleus, which projects its 
fibers to the limbic area and brainstem areas. Some POMC-containig 
fibers descend to the spinal cord (Smyth, 1983). In the human brain 
the distribution of POMC is believed to correspond to areas where 
electrical stimulation can produce pain relief (Pilcher, 1988). 
Peptides from POMC occur in both the pars intermedia and the pars 
distalis of the pituitary (Smyth, 1983). 
The precursor molecule POMC and its derived peptides are not 
confined to the central nervous system. The use of biochemical 
techniques have shown that B-EP is found in a number of tissues. B-
EP has been found in the gastrointestinal tract of rats and humans 
(Orwoll et al., 1980; Matsumura et al., 1982). Extracts from porcine 
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pancreas have shown to contain B-EP-like polypeptides with a high 
molecular weight (Houck et al., 1981). B-EP has also been detected in 
human pancreas (Bruni et al., 1979) and shown to be localized in 
pancreatic D-islets of rat, guinea pig, and man (Watkins et al., 1980). 
Glucagon-containing secretory granules of rat pancreatic alpha cells 
were shown to contain B-EP immunoreactivity as well (Grube et al., 
1978). To rule out the possibility that pancreatic B-EP is of pituitary 
origin and simply accumulated in alpha cells by an uptake of 
circulating B-EP, Grube et al (1978) examined pancreatic alpha cells 
of hypophysectomized rats and noted that they contained B-EP. The 
absence of positive immunocytochemical staining when using an 
antibody against ACTH provides evidence that pancreatic B-EP may 
not have the same biosynthetic pathway as pituitary B-EP (Bruni et 
al., 1979; Grube et al., 1978). However, in some studies the existence 
of B-EP and beta-LPH in the pancreatic tissue could not be 
demonstrated (Stern et al., 1982; Polak et al., 1977). 
Several studies demonstrated the presence of enkephalin and B-
EP-like material in the adrenal glands of several species, including 
humans (Imura et al., 1983). Additionally, enkephalins were found in 
splachnic nerves innervating the adrenal medulla (Schultzberg et al., 
1978). Opiate receptors have been identified on adrenal tissue 
(Chevkin et al., 1979; Dave et al., 1985). B-EP has also been be 
detected in stomach (Tanaki et al., 1982) and placenta (Liotta et al., 
1982). The extent of the distribution of B-EP suggests that B-EP is 
likely to be involved in both central and peripheral functions. 
18 
C. Opioid receptors. 
The primary functional sites of action for the opioid peptides 
seem to be mu, delta, and kappa receptors. The mu and kappa 
receptors are activated when appropriate ligands bind to them, 
whereas they are inactivated when bound by competitive 
antagonists (Gero, 1986). Less is known about the binding 
characteristics of delta receptors. Table 1 shows the reported affinity 
characteristics of the opioid receptors for various ligands. The delta 
receptors have a high affinity for both enkephalin and endorphin, 
kappa receptors are more inclined to bind dynorphin, whereas mu 
receptors have a high affinity for B-EP (as well as morphine and 
naloxone). Herz (1984), proposed that receptor affinity may be 
related to peptide chain length. 
While it has been proposed that m-receptors could be 
subdivided into mux and mu2 receptors (Pasternak and Wood, 
1986), it should also be pointed out that some believe mu and delta 
receptors are in fact a single fluid macroreceptor, capable of different 
binding properties when influenced by changing cellular conditions 
(e.g. altered Na+, nucleotides, or pH levels) (Blume, 1980; Bowen et 
al., 1981). However, kappa receptors appear to be distinctive and 
may act to oppose some mu supported actions (Shippenberg & Herz, 
1986). Variations of these basic opioid receptors do exist (Holaday & 
Tortella, 1984). 
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Lieand delta mu kappa 
Agonists High Low Low 
Leu-Enkephalin High Low Low 
Met-Enkephalin High High Low 
B-EP High High Low 
Dynorphin Low Low High 
Morphine Low High Low 
Antagonists 
Naloxone Low High Low 
Table 1. Relative ligand interactions with opioid 
receptor subtypes (Adapted from Paterson et al., Br. Med. 
J., 39:31-36, 1983). 
Naloxone-
Opioid antagonists are substances that interact with opioid 
receptors because of their chemical similarity to opioids while 
exerting little or no agonist effect. Opioid competitive antagonists are 
capable of displacing the opioid molecule from the receptor site, 
which reduces the physiologic effects of the opioid agonists. However, 
some of these substances may exert opioid effects. 
Opioid antagonists can result in various degrees of agonistic or 
antagonistic effects. Naloxone, a pure antagonist, is considered the 
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drug of choice in most situations that require an opioid antagonist. 
The physiological response to opioid antagonists depends upon the 
following factors: 
1. The degree of agonistic action of the chosen drug. 
2. Whether or not opioid drugs are present at the receptor site. 
3. The presence of endogenous endorphins or enkephalins at the 
receptor site. 
4. The degree of physical dependence on opioids previously 
developed by the recipient. 
5. Concentration at the receptor site as determined by dosage. 
Naloxone is a derivative of noroxymorphone, which was 
originally synthesized as a structural analog of morphine. Naloxone's 
chemical structure has an allyl group which makes it an antagonist 
(figure 3 shows the chemical structure of naloxone). Naloxone has a 
biological active life of 20 to 60 minutes, depending administration 
(Kaufman et al., 1989; Ngai et al., 1976). Plasma concentration peaks 
within 2 to 3 minutes following an intravenous bolus, but peak 
pharmacological activity lags the administration by approximately 30 
minutes. Simply measuring plasma naloxone concentration is 
inadequate for assessing the pharmacodynamic actions of naloxone. 
Naloxone is usually injected as a naloxone hydrochloride solution. 
Naloxone readily crosses the blood brain barrier (BBB) (peripherally 
administered naloxone has a 10 fold higher brainrblood ratio than 
morphine), and CNS levels turn over slower than peripheral levels. 
At high doses (in excess of 1 mg*Kgr~l), naloxone may elicit some 
agonistic activity, but it is an essentially pure antagonist at doses 
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below this level. Naloxone acts primarily on the mu opioid receptors 
but has some affinity for the kappa opioid receptors. Naloxone is 
excreted by the kidney. Naloxone sometimes can cause nausea and 
vomiting and can aggravate hypertension. 
CH2-CHrCH2 
I 
HO 
HO 
Figure 3. Chemical structure of Naloxone. 
Metabolic functions of Beta-Endorphin 
Claude Bernard's classic observation in 1855 that central 
morphine administration yields hyperglycemia provided the 
stimulus for work characterizing the consistent increase in blood 
sugar in response to morphine administration in a' number of 
mammalian models, including humans. Following the discovery of the 
E.O.P. system, evidence was presented to suggest that Beta-Endorphin 
plays an integral role in normal fuel metabolism. Research implicates 
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B-EP in the metabolic regulation of both glucose and fat stores. The 
following discussion presents a thorough description of evidence 
implicating B-EP as a regulator of glucose metabolism. 
Beta-Endorphin and Glucose Regulation. 
The demonstration that Endogenous Opioid Peptides (EOP) are 
widely distributed in sites involved in glucose homeostasis, including 
the central and peripheral divisions of the autonomic nervous 
system, the pancreas, the gut, and the hypothalamopituitary axis has 
led to the suggestion that B-EP may participate in the regulation of 
glucose homeostasis (Krieger, 1980, 1983). 
Responses of B-EP to hypoglycemia and negative energy 
balance. 
Research has indicated that disturbances in glucose homeostasis 
and food deprivation brings about changes in the B-EP synthesis and 
release (Nakao et al., 1979). It was shown that hypoglycemia induced 
by insulin administration resulted in increased B-EP release (Nakao 
et al., 1979; Radosevich et al,, 1988). In a more recent study, Kjaer et 
al (1993), noted that insulin-induced hypoglycemia stimulated ACTH 
and B-EP secretion (ACTH and B-EP are parts of the same precursor 
molecule of POMC and are co-released). In this study, a negative 
correlation (-0.91) was found between glucose and plasma B-EP 
levels. It was suggested that hypoglycemia was a potent stimulator 
of ACTH and B-EP secretion independent of insulin. It was indicated 
that this action maybe explained by the observed time lag between 
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insulin administration and ACTH response. The ACTH response did 
not occur until glucose in the cerebrospinal fluid (C.B.F.) reached low 
levels (Keller-Wood, 1981). Glucose clamping within the brain 
(infusion of glucose in the carotid arteries) during insulin infusion 
eliminated the ACTH response (Keller-Wood, 1981). These findings 
confirm other experimental results that insulin-induced 
hypoglycemia increased the pituitary POMC mRNA levels and this 
increased response can be inhibited by B-EP infusion (Suda et al., 
1992). However, a few studies failed to observe any elevations in 
plasma B-EP in response to insulin-induced hypoglycemia (Liotta et 
al., 1978; Suda et al., 1978). 
Insulin was the major tool to cause hypoglycemia in most 
studies conducted in this area. In the study of Zelissen et al. (1991) 
where diet was manipulated in order to alter plasma glucose levels, 
both a predominantly carbohydrate diet or a predominantly fat diet 
did not succeed to elicit a significant change of plasma B-EP 
concentration. In contrast, one week of carbohydrate deprivation 
resulted in a significant elevation of central and peripheral B-EP 
levels in rats (Fatouros et al., unpublished observations, 1994). In 
this study a significant negative correlation between B-EP and 
plasma glucose levels was obtained. 
However, not only induced hypoglycemia was found to elicit a 
significant response in B-EP release, but starvation or food 
deprivation conditions were found to drastically change B-EP release 
both centrally and peripherally. It has been demonstrated that a 
negative energy balance during exercise resulted in a greater 
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increase in B-EP concentration than when the subjects were in 
energy balance (Walberg-Rankin et al., 1992). An even more drastic 
alteration of energy balance, such as that induced by starvation, 
resulted in an increase of pituitary B-EP (Margules, 1979). A 
significant increase (16-43%) in the pituitary B-EP was observed 2-4 
days following food deprivation and similar increases were seen in 
B-EP located in hypothalamus and striatum but not in plasma 
(Kuldeep et al.,1985). It was suggested that the stimulation of food 
intake in rats exposed to 24 hours of food deprivation is associated 
with increased plasma B-EP (Davis et al.,1983). Finally, when food 
deprived rats were fed normal food for 24 hours, B-EP returned to 
basal levels, indicating that the food deprivation B-EP response was 
reversible (Kuldeep et al., 1985). 
Proposed mechanisms of the B-EP elevation in 
hypoglycemia. 
Histamine, a central nervous system neurotransmitter, has been 
proposed by a number of investigators as a possible mediator of B-EP 
elevation in response to insulin-induced hypoglycemia. Insulin-
induced hypoglycemia increased the turnover rate of neuronal 
histamine in the hypothalamus (Kjaer et al., 1993). It has also been 
shown that hypoglycemia elevates the release of histamine from 
hypothalamic tissue in vitro (Kjaer et al., 1986). However, histamine 
has no direct effect on the release of ACTH and B-EP from pituitary 
tissue in vitro (Hashimoto et al., 1979; Vermes et al., 1980). This 
indicates that the effect of histamine in hypoglycemia on B-EP is 
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exerted by an action at the level of the hypothalamus. This 
observation is in agreement with the finding that postsynaptic 
blocking of histamine and blocking of histamine synthesis attenuated 
the B-EP and ACTH responses to insulin-induced hypoglycemia (Kjaer 
et al., 1993). 
An alternative hypothesis is that hypothalamic releasing factors 
are the mediators of B-EP and ACTH elevation in hypoglycemia. Since 
lesioning of the mediobasal hypothalamus inhibits the ACTH 
response to hypoglycemia (Mezey et al., 1984; Jesova et al., 1987; 
Aizawa et al., 1981; Karteszi et al., 1982). Support for this hypothesis 
is the observation that hypoglycemia stimulates the release of the 
Corticotrophic Releasing Factor (CRH) in the pituitary portal blood 
(Caraty et al., 1990; Plotsky et al., 1985; Guillaume et al., 1989; Engler 
et al., 1989) and in the peripheral plasma (Sumitomo et al., 1987; 
Baylis et al., 1980). In addition, Suda et al. (1992), suggested that B-
EP can inhibit the insulin-induced hypoglycemia elevation of POMC 
mRNA levels. This effect was due to inhibition of CRF release 
(through negative feedback inhibition) by hypothalamus since CRF 
induces POMC expression. 
Recent research links together the above two hypotheses. 
Central administration of histamine or histamine agonists led to 
increased levels of CRF in peripheral plasma and pituitary portal 
blood (Kjaer et al., 1991, 1993), and immunoneutralization of 
endogenous CRF inhibited the ACTH and B-EP responses to histamine 
(Kjaer et al., 1992). This was further supported by the finding that 
histaminergic neurons originating in the posterior hypothalamus 
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project to the paraventricular and supraoptic nuclei (Panula et al., 
1989; Inagaki et al., 1988) where CRF neurons are localized (Swanson 
et al., 1983; Piekut et al., 1986; Whithall et al., 1988). Naloxone, a B-
EP antagonist, reduced the insulin-induced hypoglycemia increase of 
B-EP indicating that the hypoglycemic release of B-EP might be 
mediated through mu opioid receptors (Nush et al., 1989). 
B-EP responses to hyperglycemia. 
Sustained hyperglycemia did not affect plasma levels of B-EP 
and this result was not affected by prior exercise (Farrell et al., 
1986). B-EP concentration was unaffected by a hyperglycemic clamp 
(Ritter et al., 1990). In contrast, oral or intravenous glucose 
administration resulted in elevated plasma B-EP (Getto et al., 1984; 
Scavo et al., 1987). 
In summary, from the research findings presented no definitive 
conclusions can be drawn about the effects of hyperglycemia on the 
release of B-EP. It appears that hypoglycemia (usually caused by 
insulin administration) and starvation (food deprivation) is a 
powerful stimulus for the increase of B-EP both centrally or 
peripherally. The physiological significance of this B-EP response is 
not clear although a role as a counterregulatory agent has been 
speculated. The effects of B-EP on the glucoregulatory mechanism 
needs to be examined. 
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Beta-Endorohin Effects on Glucose Regulation. 
A. In humans. 
In two of the classical studies in this area, a single intravenous 
bolus of B-EP in normal human subjects resulted in hyperglycemia 
(Reid et al., 1981; Feldman et al., 1983). It was unclear if this was a 
direct B-EP effect or mediated by the pancreatic hormones or 
sympathetic hormones. B-EP-induced hyperglycemia is probably not 
mediated through growth hormone since in acute experiments 
growth hormone does not cause hyperglycemia (Fineberg et al., 1984; 
Sirek et al., 1979). 
B. Central effects of B-EP in animals. 
B-EP-induced hyperglycemia was observed not only in humans 
but also in animal and in vitro experiments with both central and 
peripheral administration of B-EP. A rise in blood sugar was obtained 
with a small dose of B-EP injected into a lateral cerebral ventricle 
(Borison et al., 1962; Feldberg, 1972). Intraventricular injection of B-
EP or morphine leads to a rapid elevation of blood glucose in cats and 
rats (Borison et al., 1962; Feldberg, 1972). These observations agree 
with the finding that direct injection of B-EP into the rat brain 
produces prolonged, naloxone-blocked elevations of blood glucose 
(Appel et al., 1987; Brown et al., 1979). Central infusion of B-EP after 
2-deoxy-glucose administration increased glucose utilization in the 
brain (Ableitner et al., 1992). Naloxone, a B-EP antagonist, was able 
to diminish the hyperglycemic response to central nervous system 
glucose deprivation (Ipp et al., 1984). Feldberg (1985), suggested 
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that the site of hyperglycemic action of B-EP and other opioids after 
intraventricular and intracisternal injection is the ventral surface of 
the brainstem. The central action of B-EP seems to involve 
cholinergic mediation, since prior intracisternal administration of 
hemicholinium-3, a substance which dramatically decreases 
acetylcholine concentration in the brain, inhibits increases in blood 
glucose by centrally infused B-EP (Van Loon et al., 1981). 
Another possible mediator of central action of B-EP could be 
somatostatin since intracisternal administration of this 
neurohormone also blocks the hyperglycemic effect of central B-EP 
(Van Loon et al., 1981). A third mechanism of centrally-induced 
hyperglycemia by B-EP involves sympathetic mediation. The 
evidence for this is based on the observation that intracisternal 
administration of synthetic human B-EP in conscious adult male rats 
increased plasma epinephrine concentration, while adrenal 
denervation totally inhibited the catecholamine response to the 
opioid (Van Loon et al., 1981). In addition, morphine or B-EP induced 
hyperglycemia was reduced by sectioning the sympathetic ganglia or 
adrenal ablation (Borison et al., 1962; Feldberg, 1972). From these 
observations it seems that the central effects of B-EP on plasma 
glucose levels are not directly mediated. 
Peripheral administration of naloxone was found to block the 
hyperglycemic effect of central B-EP, suggesting the involvement of 
specific opiate receptors (Van Loon et al., 1981). In contrast, in cat, 
the effects of centrally infused morphine (also an opiate agonist) 
were not antagonized by naloxone (Ramahadran et al., 1990). In 
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dogs, a high dose of central naloxone administration attenuated 
hyperglycemia produced by intracerebroventricular injection of 2-
deoxy-D-glucose (Ipp et al., 1984). More work needs to be done in 
this area in order to confirm the central actions of B-EP. 
C. Peripheral effects of B-EP in animals. 
Peripheral administration of B-EP has not produced as consistent 
results compared to centrally administered B-EP. B-EP intravenous 
infusion in rats increased basal glucose levels from 170 to 250 
mg*dl"l ten minutes after the infusion and returned to about the 
initial level after 20 minutes (Matsumura et al., 1984). In rabbit, B-
EP caused a rise in blood glucose when it was given intravenously 
(Rudman et el., 1983). However, the intravenous infusion of B-EP in 
dogs failed to observe a rise in plasma glucose concentration 
(Radosevich et al, 1984, 1989). 
D. In vitro experiments. 
In vitro studies have complicated the picture even more. 
Increased glucose release in the medium was noted when liver cells 
from fed rats were incubated in the presence of B-EP (Matsumura et 
al.,1984). Similar results with isolated hepatocytes were obtained 
when B-EP, but not morphine, was added in the medium (Allan et al., 
1983; Leach et al., 1985). In contrast, Brubaker et al. (1987) could 
not replicate these observations with physiological and 
supraphysiological doses of B-EP to isolated rat hepatocytes. In this 
study, B-EP did not alter hepatic glucose production and glycogen 
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phosphorylase-a activity (a key glycogenolytic enzyme). 
Discrepancies were explained by methodological differences between 
the aforementioned studies such as mediums used, species selected, 
doses, etc. 
Table 2 presents a summary of the effects of different modes of 
B-EP infusion on plasma glucose concentration. 
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Study Infusion Species Effect on glucose 
Reid, 1981 i.v. Humans Increase 
Feldman, 1983 . i.v. Humans Increase 
Borison, 1962 i.c.v. Cats Increase 
Feldberg, 1972 i.c.v. Rats Increase 
Appel, 1987 i.c.v. Rats Increase 
Brown, 1979 i.c.v. Rats Increase 
Ableitner, 1992 i.c.v. Rats Increase 
Van Loon, 1981 i.e. Dogs Increase 
Radosevich, 1989 i.c.v. Dogs Increase 
Matsumura, 1984 i.v. Rats Increase 
Rudman, 1983 i.v. Rabbits Increase 
Radosevich, 1984 i.v. Dogs Decrease 
Radosevich, 1989 i.v. Dogs No change 
Allan, 1983 in vitro Rats Increase 
Leach, 1985 in vitro Rats Increase 
Brubaker, 1987 in vitro Rats No change 
Matsumura, 1984 in vitro Rats Increase 
Table 2. Effects of B-EP infusions on glucose 
concentration, i.v. denotes intravenous, i.c.v. denotes 
intracerebroventricular, and i.e. denotes intracisternal. 
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Proposed mechanisms for the B-EP induced 
hyperglycemia. 
Plasma glucose concentration reflects only the balance of the 
rate of glucose production or appearance and the rate of glucose 
clearance or uptake of glucose by peripheral tissues. If B-EP has a 
hyperglycemic affect, one would expext to either increase glucose 
production, decrease glucose clearance or uptake or both. Radosevich 
et al. (1989) reported that intracerebroventricular infusion of B-EP 
caused an increase of glucose production and a decline of glucose 
clearance leading to hyperglycemia. A similar infusion protocol, by 
Nush et al. (1989), showed that B-EP led to an increase in both 
glucose production and utilization. This resulted in no change of 
plasma glucose concentration. However, in the latter study B-EP was 
administered after insulin-induced hypoglycemia. Another study, 
which employed peripheral B-EP administration, observed an 
inhibition of both glucose production and glucose uptake (El-Tayeb et 
al., 1985). Increased glucose production was also reported by a 
number of studies (Matsumura et al., 1984; Allan et al., 1983; Leach 
et al., 1985). However, two studies, one in vivo ( Radosevich et al., 
1989 ) and one in vitro (Brubaker et al., 1987) could not confirm 
these findings. These two studies showed that B-EP did not affect 
plasma glucose or glucose turnover. 
The findings presented in the last paragraph suggest that B-EP 
increases glucose synthesis or production. In order for B-EP to 
increase glucose synthesis or production one of two mechanisms 
must operate: either glycogenolysis or gluconeogenesis. Enkephalin, 
33 
another endogenous opioid peptide, induced an increase in 
glycogenolytic rate in rats in vitro. This effect was independent of 
cAMP stimulation since cAMP levels in the liver were unchanged 
(Allan et al., 1983). Matsumura et al. (1984) demonstrated that B-EP 
was capable of inducing glycogenolysis. This effect was dose-
dependent and cAMP-related. The results by Matsumura et al. 
(1984) were indirect evidence since it was shown that B-EP can bind 
to nonopiate receptors in rat liver which are coupled to adenylate 
cyclase. Activation of these receptors resulted in increased level of 
cAMP (Dave et al., 1985). Brubaker et al. (1987) observed no 
alteration in glycogen phosphorylase-a activity after B-EP addition in 
rat hepatocyte medium. 
Gluconeogenesis is the other metabolic pathway of increasing 
glucose production. Morphine infusion in rats, an opiate which binds 
to the same opioid receptors as B-EP, resulted in an increase of 
glucose synthesis by liver slices. This was a result of both an 
induction of a number of gluconeogenic enzymes and a suppression 
of pyruvate kinase (Wong et al., 1981). Enkephalins induced an 
elevation in glucose synthesis from pyruvate [2-14c] in vitro but 
morphine did not (Allan et al., 1983). In this study, naloxone had no 
effect on either the basal or stimulated rate of glucose output, 
although it significantly depressed the basal rate of incorporation of 
label into glucose and decreased the degree of stimulation by 
enkephalin by 30%. These results suggested that B-EP could have 
similar action. Indeed, the first evidence came from the observation 
that naloxone infusion was able to decrease glucose production in the 
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conscius dog despite a rise in plasma glucagon and no change in 
plasma insulin (Werther et al., 1981). This may indicate that the 
gluconeogenic pathway is under some degree of tonic control by 
opioid receptors. It was demonstrated that B-EP induced 
gluconeogenesis in vitro, after the addition of L-lactate in the 
medium from isolated rat cells (Matsumura et al., 1984). 
In summary, research suggests that central administration of B-
EP induces hyperglycemia. A concesus has not been reached 
concerning peripheral effects of B-EP on glucose homeostasis. In 
order to explain the hyperglycemic effect of B-EP, an increase in 
glucose production or an inhibition of glucose clearance or both have 
been proposed. Nevertheless, there is no agreement in this area. In 
the following paragraphs the research backround obtained on 
hormonal control will be presented. 
Beta-Endorphin Effects on Pancreatic Hormones. 
The effects of B-EP on plasma glucose concentration supports the 
notion that B-EP-induced hypoglycemia is secondary to its effect on 
pancreatic hormones. Thus, researchers attempted to assess the 
effects of B-EP on insulin and glucagon. A great deal of controversy 
exists, at least, for the B-EP effect on insulin synthesis and release. 
A. In humans. 
B-EP infusion at low pharmacological doses (0.05 mg*h"l) under 
pancreatic clamp with somatostatin infusion, did not affect plasma 
glucose turnover rate (production, utilization and clearance) (Paolisso 
35 
et al. 1987). However, in the same study, in the absence of the clamp, 
B-EP at the same dose caused hyperglycemia, indicating that the 
metabolic effects of B-EP are a consequence of the changed hormonal 
millieu and not the expression of intrinsic metabolic properties of the 
opioid. Thus, B-EP-induced hyperglycemia in normal subjects is 
probably a secondary effect to its regulation on pancreatic hormones. 
A single intravenous bolus (2.5 mg*kg~l) of B-EP increased plasma 
insulin and glucagon levels in women (Reid et al., 1981). Feldman et 
al. (1983) found a bell-shaped dose-response curve for the effects of 
B-EP on insulin. The threshold dose for B-EP was 5 ug, with a 
maximal insulin response obtained after a 50 ug bolus. The highest 
dose tested (2.5 mg) produced only small changes in plasma insulin. 
It is still uncertain whether B-EP effect on glucose homeostasis is 
direct or indirect. Research presented in the last paragraph suggested 
that, in humans, the opiates stimulate the release of both insulin and 
glucagon but they increase glucagon more than that of insulin. This 
results in an increased glucagon to insulin molar ratio which may 
play a major role in the opioid-induced hyperglycemia (Reid et al., 
1981; Feldman et al., 1983). 
E. In vivo experiments. 
In contrast with the Paolisso et al. (1987) study in humans, 
Radosevich et al. (1984) showed that a low dose of B-EP (0.2 
mg*h"l) in conscious dogs resulted in a fall in plasma glucose 
concentration. This effect was observed in the absence of changes in 
circulating levels of insulin, glucagon, catecholamines, and Cortisol. 
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This was controlled, in part, by clamping pancreatic hormones at 
basal levels with somatostatin plus intraportal replacement of insulin 
and glucagon. These authors suggested that the hypoglycemic effect 
of B-EP was not mediated by other hormonal changes. 
There are several studies that used a central B-EP infusion to 
examine its role in regulating glucose homeostasis. Intracisternal 
infusion of B-EP in rat increased plasma insulin and its half-life. This 
decreased blood glucose but was reversed by naloxone (Bartolome et 
al., 1989). Intracerebroventricular administration of B-EP in dogs, 
increased peripheral insulin two fold while glucagon remained the 
same (Radosevich et al., 1989). However, in these two studies, central 
B-EP produced hypoglycemia since insulin release was not 
accompanied by glucagon stimulation. Beta-LPH injected 
intravenously at 10 mg*kg~l in fed rabbits increased plasma insulin 
within ten minutes (Schwandt et al., 1981). Green et al. (1980) 
suggested that the stimulatory effect of opioids on insulin secretion 
has been found to be rapid and transitory during continuous 
perfusion of the pancreatic islets with enkephalin and morphine (but 
not B-EP in this study). Insulin returned to baseline during the non-
infusion period (Green et al., 1980). 
Numerous other studies produced opposite results, describing an 
insulinopenic (fall of plasma insulin) effect of B-EP both in vivo and 
in vitro: in the rat, B-EP infusion decreased plasma insulin and 
increased plasma glucagon and somatostatin (Matsumura et al., 
1984). In dogs, B-EP administration attenuated the epinephrine-
induced release of glucagon and insulin but did not modify basal 
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pancreatic alpha and beta cell secretion (Tannenlbaum et al., 1979). 
In rabbit, B-EP inhibited insulin release, while it potentiated 
glucagon release (Schleicher et al., 1987). B-EP caused inhibition of 
insulin secretion which was not blocked by naloxone (Rudman et al., 
1983). This suggested that the effect of B-EP on insulin was not 
mediated by |i-receptors. In addition, the lack of response to D-ala2-
D-leuS-ph-endorphin or etorphine appears to exclude a delta or 
epsilon receptor. Furthermore, the same study, noted that almost the 
entire free B-EP structure (1-31) was required for the in vivo 
insulinopenic response. 
Finally, several studies have noted that B-EP does not cause any 
changes in the release of insulin. Intravenous B-EP infusion in dogs 
did not affect insulin and glucagon release (Radosevich et al., 1989). 
Infusion of B-EP at 0.5 mg*h-l did not affect plasma insulin. This 
occured despite plasma glucose increasing (Paolisso et al., 1987). 
Passive immunization of rats with B-EP antibodies did not change 
basal plasma insulin release. These authors have questioned the 
physiological role of B-EP in the regulation of insulin secretion (El-
Tayeb et al., 1985). 
C. Studies with naloxone. 
Naloxone has been used to evaluate if B-EP influences pancreatic 
endocrine function through a mu opioid receptor activation. 
Unfortunately, this methodology added to the discrepancy that exists 
in this field. Studies with naloxone indicate that endogenous opioid 
peptides stimulate insulin secretion which could result in decreased 
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insulin sensitivity (Locatelli et al., 1985; Schusdziarra et al., 1984). 
Naloxone was able to reverse the effects of centrally administered B-
EP, lowering insulin release (Bartolome et al., 1989). However, some 
hormonal effects of B-EP are resistant to naloxone (Feldman et al., 
1983). 
In contrast, injection of naloxone in dogs did not block glucose, 
glucagon, and insulin responses to B-EP (Tannenbaum et al., 1979). 
B-EP-induced inhibition of insulin secretion was not blocked by 
naloxone in rabbits showing that the insulinopenic effect of B-EP was 
not mediated by receptor subtypes associated with opioid activity 
(Rudman et al., 1983). Naloxone failed to produce any effect on basal 
somatostatin and glucagon release. The authors indicated that there 
was not a persisting "tonic" in vitro action of endogenous opioid 
peptides that can be blocked by the antagonist, but does not exclude 
such an action in vivo in an intact pancreas (Ipp et al., 1984). In 
contrast, naloxone was found to stimulate the release of insulin in 
dogs without affecting glucagon (Ipp et al., 1978). 
In general, naloxone partially reverses the action of opioids on 
pancreatic hormone secretion in vitro (Green et al., 1980, 1983; 
Hermansen et al., 1983; Ipp et al., 1978; Kanter et al., 1980; Pierluissi 
et al., 1981; Ryder et al., 1980). The effects of B-EP on insulin 
secretion from rat and rabbit pancreas are not antagonized by 
naloxone (Green et al., 1983; Rudman et al., 1983). Naloxone by itself 
did not affect either glucagon or somatostatin release from pancreatic 
tissues (Hermansen et al., 1983; Ipp et al., 1978; Pierluissi et al., 
1981). 
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At present, the effect of naloxone on insulin secretion remains 
unresolved with positive (Green et al., 1983; Hermansen et al., 1983; 
Pierluissi et al., 1981) and negative findings (Kanter et al., 1980; 
Rudman et al., 1983). Feldman et al. (1983), offered three reasons 
why naloxone may not block B-EP effects: a) the dose of naloxone 
was too, small relative to the dose of B-EP. It has been shown that a 
10 to 25 fold molar excess of naloxone is needed to block B-EP effects 
in animals (Rivier et al., 1977; Chicara et al., 1978), b) B-EP effect on 
human pancreas can be mediated through a non-mu-opioid receptor, 
c) B-EP might act through a non-opiate pathway. Non-opiate 
receptors for B-EP have been described in lymphocytes and mouse 
neuroblastoma cells (Gilman et al., 1982; Hammonds et al., 1981). The 
presence of specific non-opiate receptors for B-EP in cultured human 
lymphocytes (Hazum et al., 1979), and the ability of small amounts of 
B-EP to inhibit specific [^H]-etorphine binding to bovine 
adrenomedullary membrane preparations (Dumont et al., 1983) 
strengthen the hypothesis that the peripheral action of B-EP may be 
mediated through non-opiate receptors. These B-EP receptors are not 
antagonized by other opiate agonists or by opiate antagonists (Dave 
et al., 1985). However, the fact that morphine acts through an opiate 
receptor to produce hyperglycemia argues in favor of an opiate 
receptor (Ipp et al., 1980). 
Research indicates the possibility of non-opiate binding of B-EP 
to specific non-opiate receptors. B-EP was reported to bind to 
nonopiate receptors which were coupled to adenylate cyclase in rat 
liver. Activation of these receptors resulted in increased intracellular 
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cAMP levels (Dave at al., 1985; Giugliano et al., 1989). Dave at al. 
(1985) showed that the B-EP-induced formation of cAMP was linear 
for 45 minutes. Maximal activation of adenylate cyclase activity 
(148%) was at 0.5*10 "^M of B-EP. Neither the N-terminal acetyl 
group nor the C-terminal amino acids of B-EP were essential for 
binding to the peripheral B-EP non-opiate receptors, since [1251]-
AchB-EP(l-27) competed with rB-EP(l-31) for binding on these sites. 
The midportion area of B-EP was critical for optimal receptor 
binding. In vitro, B-EP increased cAMP in liver cells in a dose-
dependent manner (Matsumura et al., 1984). B-EP in low 
concentrations increased basal cAMP levels in rat islets of 
Langerhans but it reduced cAMP at high concentrations (Ehrenreich 
et al., 1986). Furthermore, Jean-Baptiste et al. (1980), reported that 
B-EP can induce lipolysis through cAMP activation. Beta-adrenergic 
blockade during exercise impaired exercise time and induced an 
earlier onset of B-EP release (Schwartz et al., 1989). 
A few studies have suggested that there is an interaction 
between the opiate receptor and the beta-adrenergic receptor 
systems since naloxone reduced water uptake induced by 
isoproterenol (a beta-receptor agonist) (Brown et al., 1981), and 
reduced the hypotensive effect of atenolol, a beta^-adrenergic 
agonist (Laskey et al., 1989). However, other investigators suggested 
that opiates inhibit adenylate cyclase activity through functionally 
coupled receptors, guanine nucleotide-binding protein (G protein) 
(Sharma et al., 1975; Kuroseet al., 1983; Abood et al., 1985). The Gi 
inhibitory subunit of G-protein appears to be involved in the opioid 
41 
receptor-mediated inhibition of adenylate cyclase (Ui et al., 1984). 
This was supported when B-EP was reported to decrease cAMP in a 
dose-dependent manner in rat luteal cells (Kato et al., 1992). The 
possibility that B-EP interacts with non-opiate receptors, probably 
beta-adrenergic receptors, might partially explain B-EP actions, such 
as B-EP-induced liver glycogenolysis or gluconeogenesis. 
Table 3 presents a summary of the B-EP or naloxone effects on 
insulin and glucagon plasma concentrations. 
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B-EP Studies Dose Species Effect 
Feldman, 1983 5-50 ng iv bol. Humans Inc. Insulin, Glucagon 
Reid, 1983 2.5 mg iv bolus Humans Inc. Insulin, Glucagon 
Paolisso, 1987 0.5 mg/h iv Humans No change 
Bartolome, 1989 0.15-1.5 mg/gr Rats Inc. Insulin 
Radosevich, 1989 0.2 ml/h i.c.v. Dogs Inc. Insulin 
Ipp, 1978 5.5 mM in Dogs Inc. Insulin, Glucagon 
vitro 
Matsumura, 1984 5 |ig/100gr iv Rats Dec. Insulin, Inc. Glue. 
Rudman, 1983 9 nM iv Rabbits Dec. Insulin 
Radosevich, 1989 .06 mg/kg/h iv Dogs No change 
Khawaja, 1990 0.1 mg/kg ip Mice Dec. Insulin 
Naloxone Dose Species Effect 
studies 
Locatelli, 1985 0.2 mg/kg iv Humans Dec. Insulin 
Bartolome, 1989 15 ^ig/gr brain Rats Dec. Insulin 
Feldman, 1983 120nmol/kg/h Humans No effect 
Rudman, 1983 2.9*10~6M iv Rabbits No effect 
Ipp, 1984 5 mg/min icv Dogs Dec. Glucagon 
Ipp, 1978 11 mmol/1 iv Dogs Inc. Insulin 
Table 3. Effects of B-EP and naloxone on insulin and glucagon 
in plasma, iv denotes intrvenous, icv denotes intracerebroventricular, ip 
denotes intraperitoneal infusions.. 
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Proposed mechanisms of B-EP action on pancreatic 
hormones. 
There is general agreement thar B-EP stimulates glucagon 
release but its effects on insulin are equivocal. This discrepancy with 
insulin is due in part, to the dose-dependent effect of B-EP on insulin. 
It is also affected by the mode of B-EP administration. It was 
demonstrated that a dual dose-dependent effect of B-EP on insulin 
secretion in man occurs (Giugliano et al., 1987). An intravenous bolus 
(50 ug) of B-EP raised B-EP plasma levels more than 200 fold above 
basal values. It also raised plasma insulin. In contrast, constant 
infusion (50 ug*h~l) of B-EP i.v. raised plasma B-EP concentration (7 
to 8 fold) and inhibited insulin secretion. The latter response was 
associated with a rise in B-EP that was physiological. Insulin release 
was also inhibited. This is similar to the B-EP response in exercise 
(Goldfarb et al., 1987). 
Different kinetics obtained with the two routes of intravenous 
administration appear to affect insulin release. Intravenous injection 
of B-EP bolus produces high plasma B-EP concentration within ten 
minutes, while an intravenous infusion progressively increases 
plasma B-EP concentration (Paolisso et al., 1987). Different 
experimental species used in the studies presented above could have 
contributed to some of the discrepancy. 
Investigators have attributed B-EP effect on insulin and 
glucagon release to an inhibition of pancreatic somatostatin 
(somatostatin usually inhibits insulin and glucagon secretion by the 
beta and alpha cells respectively). Morphine and B-EP stimulated 
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insulin and glucagon release while inhibited somatostatin from 
perfused dog pancreas (Ipp et al., 1978). In this study, somatostatin 
inhibition by B-EP preceded insulin and glucagon elevations, 
suggesting the possibility that the primary event in opioid action 
upon the islets is the inhibition of the secretory activity of the 
somatostatin-secreting D-cells. However, two in vivo studies do not 
support a major role for somatostatin as the mediator of the B-EP 
effects on pancreatic hormone release (Schusdziarra et al., 1983). 
Another theory why insulin could be stimulated by B-EP is the 
hyperglycemia effect. A secondary rise in insulin can result in 
hypoglycemia (Reid et al., 1981). Chronic opioid administration has 
been associated with a paradoxical hypoglycemia and 
hyperinsulinism (Schmid et al., 1953; Reed et al., 1973). This 
mechanism could also explain the fall of plasma glucose that some 
investigators observed (Radosevich et al., 1984). 
Furthermore, it was suggested that B-EP synthesized in the 
pancreas can regulate insulin secretion via a paracrine mechanism. 
This action involved acute membrane effects as opposed to effects on 
the biosynthesis of insulin (Curry et al., 1987). 
An alternative mechanism is that peripherally administered B-
EP diffuses into the central nervous system where it produces its 
effects on pancreas. The circumventricular organs into the brain 
which lack the blood brain barrier can allow B-EP to be taken up 
(Pardridge et al., 1981; Radosevich et al., 1989). This hypothesis was 
also supported by the finding that there was a significant brain 
uptake of labeled B-EP (Rapoport et al., 1980). However, Houghten et 
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al. (1980), noted that intravenously injected ^H-B-EP was degraded 
rapidly at the blood brain barrier prior to entry into the brain 
hemispheres. This is in contrast to plasma B-EP which remained in 
plasma 45 minutes after injection. Therefore, based on these findings 
it does not seem likely that B-EP can diffuse into the brain area from 
the peripheral circulation. In addition, the uptake of the labeled B-EP 
was minimal (3-5 %). Therefore, it appears to be improbable that B-
EP crosses the blood brain barrier in a significant amount when it is 
given intravenously, making it difficult for peripheral B-EP to exert 
actions on the brain (Houghten et al., 1980; Radziuk et al., 1978; 
Rossier et al., 1977; Marynic et al., 1980). 
A more plausible explanation, by Giugliano et al. (1987), is that 
the prevailing glycemic state determines if B-EP will have a 
stimulatory or an inhibitory effect on insulin secretion. This 
hypothesis seems to be supported by a number of experimental 
findings. In vitro, B-EP increased insulin secretion in isolated islets 
from both lean and obese mice. However, during a glucose load 
insulin was inhibited and this effect was blocked by naloxone 
(Khawaja et al., 1990). In humans, naloxone, decreased insulin 
response to a transient glucose challenge (Locatelli et al., 1985). 
Furthermore, naloxone pretreatment decreased the insulin response 
in obese patients compared to lean controls, after an oral glucose 
challenge (Giugliano et al., 1987; Vettor et al., 1985). In contrast, in 
rabbits, when B-EP was given simultaneously with an intravenous 
glucose load, the glucose-stimulated rise of insulin was prevented 
and the clearance of the glucose load was delayed (Rudman et al., 
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1983). These observations suggest that the discrepancy that exists on 
how B-EP affects insulin secretion could be due to the differences in 
the subject's glycemic state at the time of the experiment. There is a 
trend in the research findings cited in this paragraph towards a 
stimulation of insulin secretion by B-EP when a hyperglycemic state 
prevails. One would assume that the opposite would be true (insulin 
inhibition) in a hypoglycemic condition. However, this remains to be 
established. 
In summary, B-EP effects on insulin secretion is equivocal. 
Research results appear to agree that B-EP stimulates glucagon 
release. However, B-EP action on the pancreas has not been 
determined whether is mediated by an opiate or a non-opiate 
pathway. 
Effects of Beta-Endorphin on Catecholamines. 
Catecholamines play an important role in the counterregulation 
of plasma glucose. Catecholamines stimulate liver and muscle 
glycogenolysis and lipolysis, or enhance gluconeogenesis. 
Catecholamines also stimulate the release of glucagon and inhibit the 
secretion of insulin. Researchers have examined the interelationship 
between B-EP and catecholamines (norepinephrine and epinephrine) 
both at the central and peripheral level. 
Several studies demonstrate the presence of enkephalin and B-
EP like material in the adrenal glands of several species, including 
humans (Govoni et al., 1981; Linnoila et al., 1980; Lundberg et al., 
1979). Opioid peptides were also found in splachnic nerves supplying 
47 
the adrenal medulla (Schultzberg et al., 1978). Opiate receptors have 
been localized on adrenal tissue (Chevkin et al., 1979; Dave et al., 
1985). These authors have suggested an interaction between B-EP 
and catecholamines. 
A. In vivo and in vitro experiments. 
Sectioning of the sympathetic ganglia reduced the 
hyperglycemic effect of morphine (Dey et al., 1975; Feldberg and 
Shaligram, 1972; Feldberg et al., 1983). Peripheral hyperglycemia 
induced by opioid agonist peptides such as morphine and B-EP, has 
been speculated to be mediated by an increased central sympathetic 
outflow from the adrenal medulla and peripheral sympathetic 
endings (Giugliano, 1988). This was supported by findings that 
intracisternal administration of B-EP, in conscious adult male rats, 
increased plasma epinephrine concentration, while adrenal 
denervation or intracisternal injection of naloxone totally inhibited 
the catecholamine response to the opioid (Van Loon et al., 1985 ). 
Central B-EP activation was reported to act on the paraventricular 
nucleus of hypothalamus to release catecholamines (Kiritsy-Roy et 
al., 1986; Gunnion et al., 1988). In contrast, elevated nor-adrenergic 
activity was found to be attenuated in the dienkephalon by 
endogenous opioid peptides (Gold et al., 1984). This indicated that 
opioid effects on catecholamines might vary from one brain area to 
the other. Finally, the hyperglycemic effect of morphine was found to 
be depressed when catecholamines were infused centrally (Feldberg, 
1972). This suggested some kind of negative feedback inhibition on 
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the release of B-EP by catecholamines. 
Feldberg et al. (1972) noted that morphine stimulated the 
epinephrine-induced increase in plasma glucose. This raised the 
possibility that B-EP may contribute to the stimulation of 
epinephrine release. In fact, morphine was reported to induce 
hyperglycemia by stimulating the release of epinephrine. This action 
appeared to be mediated through the central nervous system 
although the specific site of action was unclear (Feldberg et al., 1974; 
Vassale et al., 1961). Radosevich et al. (1984) confirmed these 
findings that morphine administration increased plasma 
catecholamines. An intracerebroventricular infusion of B-EP caused 
an increase in peripheral catecholamines (Radosevich et al., 1989). 
However, another study failed to demonstrate any morphine effect 
on plasma catecholamines in vivo (Taborsky et al., 1982). 
A considerable body of literature which used infusions of both 
B-EP and its antagonist, naloxone, dispute the findings presented in 
the previous paragraph. These articles support an inhibitory role of 
B-EP on the release of peripheral catecholamines. Morphine was 
reported to inhibit catecholamines (Taborsky et al., 1979). B-EP 
infusion in dogs attenuated the epinephrine release of glucagon 
(Tannenbaum et al., 1979), indicating a possible inhibition of 
epinephrine release by B-EP. Infusion of B-EP in dogs modulated the 
effects of epinephrine in the liver and inhibited catecholamine-
stimulated glucose production (El Tayeb et al.,1985). In vitro results 
suggested an inhibitory role for B-EP on catecholamine release 
(Mannelli et al., 1984). Sympathetic reflex response to both pressor 
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and depressor stimuli were attenuated by morphine or opioid 
analogs and potentiated by naloxone (Montrastrug et al., 1981; Petty 
et al., 1981). The inhibitory effect of opioids was further supported 
by a number of other studies (Illes et al., 1987; Karras et al., 1981; 
Konishi et al., 1979; Williams et al., 1979). 
B. Changes in humans. 
Increases in circulating epinephrine and norepinephrine during 
various stress conditions tend to be greater after B-EP antagonism in 
humans. Naltrexone, a B-EP antagonist, significantly elevated 
epinephrine compared to controls, but not norepinephrine during 
exercise (Farrell et al., 1986). Activation of peripheral sympathetic 
outflow during isometric exercise was enhanced by naloxone (Farrell 
et al., 1991). In addition, blocking B-EP with naloxone increased 
epinephrine at high but not low B-EP doses (Estilo et al., 1982; 
Manelli et al., 1984). Intravenous naloxone infusion during insulin-
induced hypoglycemia produced a decreased hypoglycemic response 
which was associated with increased epinephrine, glucagon and 
Cortisol (El Tayeb et al., 1986). Finally, naloxone had no effect on 
resting plasma catecholamines but decreased the insulin-induced 
hypoglycemia response (Nush et al., 1989). 
C. Effects of catecholamines on B-EP secretion. 
A small number of studies examined how catecholamines or 
adrenergic agonists, such as isoproterenol, affect B-EP secretion. In 
animal experiments, isoproterenol, a beta adrenergic agonist, 
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resulted in a dose-dependent increase in B-EP (Berkenbosch et al., 
1981; Sweep et al., 1989). According to this finding, beta adrenergic 
blockade should decrease B-EP release. However, it was shown that 
beta adrenergic blockade during exercise increased plasma B-EP 
(Schwartz et al., 1989). El-Tayeb et al. (1985) noted that repeated 
epinephrine infusions did not change plasma B-EP in dogs. Therefore, 
catecholamines effect on plasma B-EP is not clearly established. 
It is certain that more work is needed in this area in order to 
understand the interrelationship of B-EP and catecholamines. 
Lipolytic Function of Beta-Endorphin. 
Fat metabolism is a major deteminant of energy utilization both 
during resting conditions and during stress such as exercise. It is 
regulated by central and peripheral factors. Many hormones and 
neurotransmitter peptides are involved in the mediation of both 
lipogenic and lipolytic metabolic pathways. Insulin is a major 
lipogenic hormone and catecholamines, growth hormone, ACTH, 
glucagon are major lipolytic regulators. There is a significant 
interelationship between carbohydrate and fat metabolism. Excess 
carbohydrates are converted and stored as fat, and when plasma 
glucose and liver or muscle glycogen become limited, fat metabolism 
is enhanced to spare glucose. During the last decade, a substantial 
amount of experimental evidence has accumulated that implicates B-
EP in the lipolytic regulation. Therefore, lipolysis is another area of 
metabolism that appears to be influenced by B-EP. 
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Margules (1979), suggested that increased responsiveness of the 
endogenous opioid system in starvation might conserve energy by 
inhibiting sympathetics. However, an alternative view (Feldberg et 
al., 1972) supported the notion that norepinephrine was responsible 
for short-term lipolysis during starvation. After some time 
norepinephrine does not solely participate in this function and other 
substances are involved (Brodie et al., 1963; Goodman et al., 1959; 
Maickel et al., 1977; Stern et al., 1963). B-EP appears to be one of 
the substances that might be involved in long term regulation of 
lipolysis. A number of other candidates for this role exist, such as 
epinephrine, growth hormone, and ACTH. However, the involvement 
of B-EP in lipolysis is beyond the scope of this study. 
Beta-Endorohin Responses During Exercise 
Exercise intensity increases the plasma levels of most hormones. 
The explanation for an increase in many of the endocrines can be 
linked either directly or indirectly with exercise metabolism. 
However, there is not enough evidence to implicate the endogenous 
opioid system with exercise metabolism. A major question related to 
the exercise-B-EP literature is the role of B-EP in metabolic 
regulation. It is difficult to assign any direct significance of plasma B-
EP to tissue responses during exercise. Careful studies need to be 
conducted in order to determine the role of B-EP on metabolism 
during exercise. 
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A. Effects of Exercise on Central Beta-Endorphin. 
Although knowledge of peripheral opioid functions is rapidly 
accumulating, the best characterized opioid systems are still in the 
central nervous system. Despite this fact, most research into exercise 
and opioids has determined peripheral effects. Only a limited 
number of studies have investigated central opioid activity with 
exercise. Exercise appears to influence central endorphin function, 
but no systematic conclusions can be drawn at present. In addition, 
most of this work has employed animal models, making implications 
for human responses difficult. 
Prolonged exercise was shown to alter opioid peptide content in 
discrete brain areas, but not throughout the brain (Blake et al., 
1984). B-EP and leu-enkephalin in the nucleus acumbens were 
increased by exercise. However, this could indicate either an increase 
synthesis or a decreased release. Twenty to thirty minutes of 
swimming resulted in a significant decrease in hypothalamic B-EP in 
rats (Wardlaw et al., 1980). However, this finding was not confirmed 
by a study which used sprint running (Metzger, 1984). Furthermore, 
Sforzo et al. (1986), found increased binding of an opioid antagonist 
(^H-diprenophine) in five brain regions following two hours of warm 
water swimming. This could indicate a decreased opioid release 
following exercise providing decreased competition to the injected 
ligand for available receptors. It also could suggest B-EP release to 
other areas or increased receptors. Decreased C-carfentanil (a |a.-
receptor agonist) binding following treadmill exercise was observed 
using positron emmission tomography (Wagner et al., 1986). 
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Hoffmann et al. (1990), observed a significant increase in B-EP 
concentration in cerebrospinal fluid of rats trained to run 
spontaneously compared to sedentary controls. 
In summary, reports on exercise-induced changes in central B-
EP are inconsistent. More information is needed to confirm that 
exercise influences central B-EP response. 
B. Effects of exercise intensity on Peripheral Beta-
Endorphin. 
Peripheral B-EP levels increased from resting values after a 
graded exercise test in all studies. The magnitude of this exercise-
induced increase in plasma B-EP ranges from 1.5 fold (Goldfarb et al., 
1987) to 7 fold (Olehansky et al., 1990). The variation in findings 
might be partly due to methodology since both the intensities and 
durations at each stage varied. In addition, different types of 
exercise and different protocols to determine intensities were used. 
Another explanation for the varying increases in B-EP levels might 
be a variable degree of exhaustion and method to measure B-EP. 
Investigators have suggested that exercise-induced increase in 
B-EP is intensity dependent (Colt et al., 1981; Donevan et al., 1987; 
McMurray et al., 1987; Rahkila et al., 1987; Goldfarb et al.,1990), 
whereas others had contradictory findings (Farrell et al., 1982; 
Goldfarb et al., 1987). DeMerleir et al. (1986), included lactate as an 
intensity-related metabolic parameter. It was assumed that B-EP 
levels in blood were dependent upon anaerobic metabolic demand. 
During a graded exercise test, at a RER of 0.85 and a lactate 
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concentration of 3 mmol*l~l no significant changes in B-EP levels 
were noted. In contrast, at exhaustion, B-EP levels increased in 
parallel to lactate values. It was also shown that B-EP increased 
significantly during exercise above the lactate threshold (75% of 
V02max) and after the cessation of exercise almost 3.6 fold 
(Schwartz et al., 1990). Thus, according to the authors, the point of 
overproportional increase in lactate concentration and B-EP level is 
coincident. In addition, maximal increases in B-EP correlated with the 
maximal lactate levels suggesting a connection between the extent of 
the B-EP increase and anaerobic metabolism. Mougin et al. (1987) 
reported a significant correlation (0.6) between plasma lactate and B-
EP concentrations after a long distance nordic ski event. However, it 
must be underlined here that a significant correlation between the B-
EP and lactate responses does not establish a cause and effect 
relationship. In addition, these high correlations between B-EP and 
lactate concentrations were observed during non-steady state 
conditions and were not obtained during steady state exercise. 
Goldfarb et al. (1991), observed a dissociation between B-EP and 
lactate concentrations during the later stages of prolonged exercise. 
In that study, increases of lactate levels at 60% of V02max were not 
accompanied by plasma B-EP elevation. Furthermore, endurance 
exercise at a lactate steady state was not able to stimulate a 
peripheral B-EP increase (Sforzo et al., 1988). 
An acute anaerobic exercise increased plasma B-EP 2-4 fold 
which was lower than that obtained with graded exercise test 
(Brooks et al., 1988; Rahkila et al., 1987; Schwartz et al., 1990). 
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As it was pointed out by Goldfarb et al. (1987), B-EP and 
exercise intensity do not have a linear relationship. It might be best 
described by a curvilinear model or more probably by a threshold 
driven release. Figure 4 demonstrates how B-EP response changes 
with exercise intensity and Tables 4 and 5 list the changes for B-EP 
in studies which employed a graded exercise test or acute anaerobic 
bout of exercise (less than 2-3 minutes), respectively. 
1S-I 
Rest (mmj EkwcIm intensity 
<% V02 max) 
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Figure 4. Responses of B-EP to varying intensities of exercise. 
(From G.A. Sforzo, Sports Medicine, 7: 109-124, 1988). 
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Reference Exercise Intensity Change 
in B-EP 
Goldfarb, 1987 Cycling Exhaustion Increase 
Goldfarb, 1990 Cycling, 30 min. 70-80% Increase 
Rahkila, 1988 Running, 10 min. < 80% No change 
>80% Increase 
Elias, 1989 Running At exhaustion Increase 
McMurray, 1987 Cycling, 20 min. <70% No change 
>80% Increase 
Farrell, 1987 Running, 7 min. 60% No change 
Brooks, 1988 Sprint, 30 sec. 100% Increase 
Sonka, 1975 Running <70% No change 
>90% Increase 
Table 4. Plasma B-EP responses to varying exercise intensities. 
(LA denotes lactate concentration). 
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Reference Exercise Lactate Cone. Change 
in B-EP 
Brooks, 1988 Running, 30 sec LA=15.6 mmol/L Increase 
Farrell, 1987 Running, 300 sec. HRmax =196 bpm Increase 
Rahkila, 1987b Running, 65 sec LA =11.5 mmol/1 Increase 
Kraemer, 1989 Cycling, 195 sec LA =10 mmol/1 Increase 
Cycling, 6-45 sec LA = 4-8 mmol/1 No change 
Schwarz, 1990 Cycling, 60 sec LA = 12 mmol/1 Increase 
Table 5. Changes in Plasma B-EP associated with an acute bout of 
anaerobic exercise (less than 3 minutes). LA denotes lactate 
concentration. 
Kraemer et al. (1993), showed that heavy resistance exercise 
increased plasma B-EP. It appears that the duration of the force 
production and the length of the rest periods between sets were 
important variables that influenced plasma B-EP with lifting 
exercises. 
Most investigations indicated that B-EP levels continue to rise 
for 5-15 minutes into recovery from heavy exercise and gradually 
return to baseline over the next 45 minutes (Sforzo et al., 1988). 
There appears to be a great intraindividual (Sheps et al., 1988) 
and interindividual variability (Donovan et al., 1987; Goldfarb et al., 
1987; Howlett et al., 1984) in B-EP response to exercise. Gambert et 
al. (1981), indicated that men had greater B-EP responses than 
women to a 20 minute run on the treadmil at 80% of the predicted 
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maximal heart rate. However, their sample size was very small. 
Finally, emotional stress of the task, i.e. the stress of competition 
or danger might contribute to the rise of circulating endorphins in 
some exercise settings (Adams et al., 1987; Oltras et al., 1987). Stress 
specific increase in plasma B-EP and ACTH levels were often not 
associated with increase in brain B-EP concentration (Rossier et al., 
1977). 
In summary, it appears that incremental graded exercise using 
both aerobic and anaerobic energy sources or short term maximal 
exercise, increases B-EP levels. There is probably a threshold exercise 
intensity that is required to elicit an increase in B-EP response which 
is above 60% V02max depending on duration. 
C. Duration of Exercise and peripheral B-EP. 
Whereas in the relationship between exercise intensity and B-EP 
response little or no conflicting results exist, there is some 
controversy in the findings on the relationship between B-EP 
response and exercise duration. It has been reported both unchanged 
(DeMeirleir et al., 1986; Elias et al., 1989; Kelso et al., 1984; Kraemer 
et al., 1989; Langenfeld et al., 1987) and markedly increased B-EP 
responses (Bortz et al., 1981; Carr et al., 1981; Dearman et al., 1983; 
Farrell et al., 1982; Gambert et al., 1981; Schwartz et al., 1989) 
during prolonged exercise. Methodological differences of the above 
studies could have resulted in this inconsistency: The antibody used 
by some studies (Carr et al., 1981; Farrell et al., 1982; Gambert et al., 
1981) had a high cross-reactivity to beta-LPH. Farrell et al. (1982), 
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used only a small number of subjects. Little information was 
presented for intensity of exercise, just maximal heart rate (Carr et 
al., 1981; Gambert et al., 1981). This workload varies from person to 
person. Some authors with the same intensity of exercise (80-85% of 
maximal heart rate) did not show any changes in B-EP levels (Bullen 
et al., 1984; Elias et al., 1989). 
One factor that might have to be considered in this discussion, is 
the intensity of the work performed during prolonged exercise. 
There might be a threshold intensity below which no changes in 
circulating B-EP are observed. DeMeirleir et al. (1986), reported no 
increase in B-EP plasma levels after one hour of cycle ergometer 
exercise at submaximal workload below the lactate threshold of 4 
mmol*l"l. Comparable results were obtained by McMurray et al. 
(1987), who showed that B-EP increased only at an intensity of 80% 
of maxV02. Goldfarb et al. (1990), used 12 college-aged men who 
completed three submaximal sessions of cycle ergometer exercise, on 
separate days at intensities of 60, 70, and 80% of maxV02. Cycling at 
60% of maxV02 did not alter plasma B-EP levels whereas at 70% and 
80% max V02 increased B-EP significantly. Two other studies found 
that long-term exercise at 60% of maxV02 did not alter plasma B-EP 
levels after one hour (Langerfeld et al., 1987; Rahkila et al., 1987). 
Furthermore, endurance exercise at a lactate steady state was not 
able to stimulate a peripheral B-EP increase (Sforzo et al., 1988). 
In summary, plasma B-EP increase with duration of exercise 
depends on exercise intensity. (Table 6 presents experimental results 
on how B-EP changes in response to prolonged exercise). 
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Reference Exercise Intensity Change 
in B-EP 
Carr, 1981 Cycling, 60 min. 85% of HRmax Increase 
Gambert, 1981 Running, 20 min. 80% of HRmax Increase 
Farrell, 1982 Running, 30 min. 60% of V02max Increase 
80% of V02max No change 
Bullen, 1984 Cycling, 60 min. 50-80% of HRmax Increase 
Kelso, 1984 Cycling, 120 min. 50% of V02max No change 
De Merleir, 1986 Cycling, 60 min. LA = 2.5 mmol/1 No change 
Elias, 1989 Running, 20 min. 80% of HRmax No change 
Langenfeld, 1987 Cycling, 60 min. 60% of V02max No change 
McMurray, 1987 Cycling, 20 min. 40% of V02max No change 
60% of V02max No change 
80% of V02max Increase 
Kraemer, 1989 Running, 30 min. HR = 55 bpm. No change 
Schwarz, 1989 Cycling, 89 min. 63% of V02max Increase 
Goldfarb, 1990 Cycling, 30 min. 60% of V02 max No change 
70% of V02max Increase 
80% of V02max Increase 
Table 3. Changes in plasma B-EP in response to endurance 
exercise. (La denotes lactate concentration, HRmax denotes Maximal 
Heart Rate, and V02max denotes maximal oxygen consumption) 
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D. Adaptations of Beta-Endorphin to Training. 
At this point in time, there is not a substantial amount of 
evidence to support a certain direction of B-EP or opioid peptides in 
general adaptation to chronic exercise. Met-enkephalin release was 
mitigated following eight weeks of training (Howlett et al., 1984). No 
rise in circulating enkephalin was shown following exercise in 
trained individuals but no pretraining comparisons were made 
(Farrell et al., 1987; Mougin et al., 1987). Exercise training was 
reported to augment B-EP response to heavy exercise (Carr et al., 
1981; Farrell et al., 1987; Mougin et al., 1987). However, it must be 
questioned whether greater absolute exercise alone, attainable by 
trained athletes, was responsible for the differences between the 
groups in cross sectional studies. Howlett et al. (1984), in a 
longitudinal study failed to support an adaptive enhancement of B-
EP release with training. In contrast, another study showed that 
maximally attained B-EP levels were inversely related to maxV02 
(Donovan & Andrew, 1987). Goldfarb et al. (1991), reported no 
difference in B-EP reponse between trained and untrained subjects 
at similar relative intensity of exercise. 
Blake et al. (1984), indicated that training decreased opioid 
activity in the amygdala of trained rats. Also, a 22-week period of 
treadmill running resulted in downregulation of the number of 
opioid receptors in rats (Houghten et al., 1986). Recent studies 
indicate that different types of training may bring about different 
effects on the release of B-EP during exercise with anaerobic or 
sprint-type training producing the largest hormonal increase 
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(Kraemer et al., 1989). It was suggested that opiates produced in the 
body during exercise are degraded more slowly in the blood of 
trained individuals compared to the untrained subjects (Jaskowski et 
al., 1989). Finally, Hoffmann et al. (1990), observed a significant 
increase in B-EP concentration in cerebrospinal fluid of rats which 
were trained to run spontaneously compared to sedentary controls 
In summary, the experimental evidence is equivocal concerning 
training effects on B-EP levels both centrally and peripherally. Some 
studies demonstrated an increase, others no change and still others a 
decrease. This may be in part, due to the type of training, the tissue 
examined and methodology. 
Metabolic Effects of Beta-Endorphin During Exercise. 
Exercice-associated increases of peripheral blood B-EP levels 
were related with changes in mood state and pain perception (Arentz 
et al., 1986; Jungkunz et al., 1983; Olausson et al., 1986; Paulev et al., 
1989; Pertovaara et al., 1982; Shyu et al., 1981). This made it 
possible to assign well known sports related phenomena, such as 
exercise-induced analgesia and "runners-high" phenomenon to a 
biochemical substance. Unfortunately, studies examining this topic 
have reported contradictory results using naloxone as the primary 
investigative tool (Cumming &Wheeler, 1987). A review published 
by Cumming and Wheeler (1987), concluded that "claims of exercise-
related improvements in mood as mediated via opioidergic pathways 
are largely hypothetical". 
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In addition to the changes of mood state found with exercise, 
there are indications that exercise-induced changes of pain 
perception are connected with increased levels of B-EP in the 
periphery. Modulation of pain was described after exercise with a 
predominantly anaerobic component (Arenz et al., 1986; 
Kempppainen et al., 1985). The authors suggested that the analgesic 
effect of endogenous opioids occurs in relation to the metabolic 
condition of increased lactate acidosis. Considering the correlation 
between exercise-induced increases in B-EP and lactate levels, the 
acidosis tolerance might therefore be influenced by endogenous 
opioids. However, these conclusions are speculative, because so far 
there is no evidence that this occurs. 
While no conclusive results have been presented for the above 
hypothesized functions of B-EP during exercise, evidence is mounting 
to suggest that opioid peptides, particularly B-EP, play an important 
role in resting metabolism. B-EP seems to have a part in both glucose 
and fatty acid metabolism. Considering the metabolic acceleration 
that accompanies exercise, the adaptations that follow physical 
training, and the opioids' potential input for these changes, it is 
surprising that opioid-regulated mechanisms have not been 
researched in respect to exercise metabolism. 
Negative energy balance during exercise resulted in a greater B-
EP increase compared to when energy balance was normal (Walberg-
Rankin et al., 1992). This finding suggests that B-EP responded to 
alterations of human metabolism during exercise. However, 
hyperglycemia, did not stimulate a rise in circulating B-EP and prior 
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exercise did not affect this lack of response (Farrell et al., 1986). This 
could mean that either a positive glucose balance does not stimulate 
a B-EP response or a hypoglycemic condition such as that obtained in 
prolonged exercise beyond two hours might be required in order to 
elicit B-EP release. 
Studies describing correlations between ACTH, B-EP and lactate 
(Buono et al., 1987; Farrell et al., 1983), assumed that substances 
resulting from anaerobic metabolism could stimulate the 
hypothalamus-pituitary axis via chemoreceptors in the muscle. 
Sympatho-adrenal activity is needed for a high glycolytic flow rate 
since glucose must be present in adequate amounts to supply this 
pathway. Animal experiments indicated that B-EP increased 
glycogenolysis and gluconeogenesis from L-lactate (Allan et al., 1983; 
Matsumura et al., 1984). Thus, it appears that the physiological 
significance of B-EP rise during exercise maybe to mediate 
glucoregulation. 
However, few studies have attempted to examine this possibility 
in human subjects. They have used naloxone infusion as their major 
research tool. Naloxone, however, can not always inhibit the actions 
of B-EP. Also, since B-EP could act indirectly and at multiple 
locations, more invasive, basic, and extensive procedures are needed. 
Both central and peripheral responses of B-EP must be examined 
since actions of centrally located B-EP probably are anatomically and 
functionally different. 
It was reported that cerebrospinal fluid glucose declined and B-
EP and ACTH increased towards the end of exercise (Radosevich et 
65 
al., 1989). These authors suggested that there was an inverse 
relationship between cerebrospinal fluid B-EP and ACTH with 
exercise intensity. The elevations in cerebrospinal B-EP and ACTH 
were not proportional to elevations in the plasma. Farrell et al. 
(1988), determined that naloxone did not affect glucose levels during 
exercise. However, plasma glucose levels were not a good indicator of 
B-EP involvement in glucose regulation since exercise causes 
significant alterations in plasma glucose concentration only after 
prolonged work to exhaustion lasting over 120 minutes. These 
conditions were not met in this study. Despite the fact that there is 
some evidence to hypothesize that B-EP might act as a 
glucoregulatory agent, there is limited information to support this 
model. 
Lipid metabolism seems to have association with B-EP. Exercise 
induces both adipocyte and muscular triglyceride breakdown. There 
have been reports of in vivo and in vitro B-EP-stimulated lipolysis 
(Richter et al., 1983). Naloxone was examined to determine if the 
opioid system was involved with exercise-induced lipolysis (Vettor 
et al., 1987). Rats swam for 60 minutes in warm water. Free fatty 
acid release was attenuated following naloxone injection when 
compared with saline-injected exercised animals. The authors 
suggested that increased lipolytic activity during exercise may, at 
least, partially be under opioid control. They suggested that naloxone 
apparently had a more general antilipolytic effect. Some evidence 
indicates a postreceptor antilipolytic effect of naloxone (Jean-Baptiste 
et al., 1980). Although this data establishes a non-causal relationship 
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between B-EP and exercise-induced lipolysis, opioid peptides might 
be involved in triglyceride metabolism during exercise. At this time 
no investigation of a potential opioid mediation of lipolysis with 
exercise appears in the literature. 
Beta-Endorphin mediated control of glucose and lipid 
metabolism during exercise might be either direct or indirect. By 
affecting other agents B-EP may act indirectly. Limited information 
has been published dealing with the issue concerning the B-EP 
relationship with the glucoregulatory hormones. 
Antagonism with naloxone was used to examine if B-EP might 
affect insulin during exercise. During sustained hyperglycemia after 
exercise, the exercise-naloxone group had reduced insulin levels 
compared to the exercise-saline group and resting-naloxone groups 
but not with the resting-saline group (Farrell et al., 1988). They 
suggested a stimulatory role of endogenous opioid peptides on 
insulin secretion. However, this study showed naloxone effects after 
and not during exercise and also used a hyperglycemic manipulation. 
As it has been previously stated, glycemic state of the subjects can 
influence B-EP response. Insulin secretion was also shown to be 
inhibited by naloxone after a prior stress (Merrill et al., 1987). No 
data exist on how B-EP directly affects insulin during exercise. 
Naloxone could not alter glucose metabolism and glucoregulatory 
hormone responses (insulin and glucagon) in a number of exercise 
studies (Bramnert, 1988; Farrell et al., 1986; Grossman et al., 1984; 
Staessen et al., 1988). These studies however, used exercise 
protocolas which lasted less than 60 minutes. Glucose metabolism 
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during prolonged exercise is disturbed only after 60-90 minutes. In 
the only study that used a 90 minute protocol, naloxone caused 
relative hyperglycemia while it did not alter insulin or glucagon 
concentrations in the plasma (Hickey et al., 1994). Nevertheless, it is 
not safe to assume that B-EP elicits the opposite results or has no 
effect on the glucoregulatory hormones due to problems with 
naloxone effectiveness a blocking agent previously mentioned. 
Prior work in both humans (Bouloux et al., 1985; Farrell et al., 
1986; Lam et al., 1986) and animals (Imai et al., 1988), demonstrated 
that increases in circulating norepinephrine during various stresses 
tend to be greater after B-EP antagonism with naloxone; yet these 
increases were not always statistically significant. At all times during 
exercise, naltrexone (another B-EP antagonist) significantly elevated 
epinephrine compared to controls, but not norepinephrine (Farrell et 
al., 1986). Lipolysis or plasma free fatty acids were unchanged in this 
study. Activation of peripheral sympathetic outflow during isometric 
exercise was enhanced by opioid antagonism with naloxone (Farrell 
et al., 1991). Eventhough this body of literature seems to agree on a 
inhibitory role of B-EP on peripheral catecholamine release, it must 
be remembered that B-EP action might be different at the brain 
level. Also, none of the above studies employed a B-EP infusion, 
either centrally or peripherally, to explore the direct effects of B-EP 
on catecholamine metabolism. Futhermore, in non-exercise settings, 
central infusion of B-EP caused catecholamine activation both 
centrally and peripherally (Van Loon et al., 1981, 1984; Radosevich 
et al., 1989), and pripheral infusion of B-EP gave contradictory 
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results. It does not seem reasonable that B-EP should inhibit 
catecholamine release and at the same time cause hyperglycemia or 
lipolysis, unless it substitutes or competes with catecholamines for 
these actions. 
Finally, there is no data to support or refute that B-EP affects 
exercise performance or running time. One study used naloxone 
which did not affect running performance (Farrell et al., 1988). 
In summary, evidence has accumulated to suggest a role for B-
EP in the control of metabolism. The application of this information to 
exercise models is sparse. 
Final considerations. 
Kjaer et al. (1989) elegantly demonstrated that afferent sensory 
input from exercising muscle is active in stimulating circulating 
levels of B-EP in humans. However, the question as to the extent to 
which central B-EP is elevated during exercise is still unanswered. 
Work with animal models suggests that central and peripheral opioid 
systems are indepedently regulated, and that elevations in 
peripheral levels can not be taken as an indication of concomitant 
central responses (Sforzo et al., 1985). Pharmacological evidence 
clearly suggests centrally mediated effects on pancreatic, adrenal, 
and hepatic responses (Giugliano, 1984), However, reliance on 
measurement of peripheral opioid peptides as an index of the 
activity of the system as a whole is problematic. The use of naloxone 
is "suspicious". It has the distinct benefit of rapid blood brain barrier 
(BBB) accessibility and can antagonize both central and peripheral 
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effects. Its non-selective nature suggests that it would antagonize 
most B-EP mediated responses. Different subclasses of opiate 
receptors may act in a modulatory or interactive fashion and non­
specific blockade may obviate the significant of these interaction. In 
addition, some B-EP effects may be mediated through non-opiate 
receptors. 
In summary, exercise of adequate intensity (> 60 % of V02max) 
and duration (>20 minutes) resulted in significant elevations of B-EP 
concentration at least in the periphery. However, it is not certain how 
training state, diet, and acute effects of preceding stressors affect this 
relationship. Despite the fact that a number of exercise manipulations 
appear to be stimulatory toward B-EP secretion, little is known about 
the physiological role that this peptide has under these 
circumstances. Data from naloxone studies suggest that B-EP may be 
involved in the subjective response in exercise, and may have a role 
in exercise capacity as judged by decreases in endurance time (11-
13%) (Hickey et al., 1992; Surbey et al., 1984). B-EP also appears to 
modify adrenal and pituitary hormone responses to exercise 
(Grossman et al., 1984). More recent data has implicated B-EP in 
post-exercise insulin secretion in an animal model, and suggested 
that B-EP could inhibit exercise-induced sympathetic activity (Farrell 
et al., 1988, 1991). 
Metabolic aspects are less clear; few investigations have 
employed exercise which is a significant fuel stressor, to determine 
the B-EP effect on metabolic regulation. Thus, the role of the B-EP in 
fuel mobilization under conditions of elevated fuel demand during 
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exercise has yet to be elucidated. In conclusion, the B-EP effect on 
glucose, insulin and glucagon during exercise needs to be determined. 
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CHAPTER III 
METHODS AND PROCEDURES 
This chapter will include the following headings: experimental 
design, subjects, sampling, treatment and analysis of samples, and 
statistical analysis. 
Experimental Design 
The purpose of this study is to investigate the effects of B-EP in 
the regulation of glucose metabolism during prolonged exercise. 
After catheterization surgery, rats were randomly assigned to one of 
three treatments (twenty four rats per group). The groups were as 
follows: a) B-EP infusion, b) naloxone infusion, and c) placebo 
infusion (normal saline). 
Subjects 
Animal subjects will be used for this study since administration 
of B-EP to human subjects is prohibited by F.D.A regulations. Ninenty 
six male Spraque-Dawley rats, weighing 250-300 grams, were 
purchased from Harlan Company, IN (It was determined by power 
statistical analysis that the animal number necessary to obtain 
statistical significance at the 0.05 level is 72. The rest of the animals 
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were used for pilot experiments and practice of the catheterization 
technique). Animals that did not recover from the surgical operation 
for catheter placement or did not survive the running protocol were 
replaced so that at least 76 animals completed the experiment. 
Animals were individually caged in the animal care facility of the 
University of North Carolina at Greensboro. The room was kept on a 
12-12 light-dark cycle at a temperature of 22 ± 1°C. Animals were 
fed a standard laboratory rat chow diet and tap water was provided 
ad libitum. Body weight and amount of food consumed was 
monitored daily in order to assure proper growth of the 
experimental animals. Approval for this study by the Institutional 
Animal Care and Use (IACUC) committee of the University of North 
Carolina at Greensboro was granted to the investigator. 
The animals arrived at the animal facility and randomly 
assigned to groups of 24. A pilot study with at least five rats was 
conducted by the investigator before the commencement of the 
actual experiment, in order to assure the proper performance of the 
protocol. This enabled him to familiarize himself with the animals, 
procedures, and instrumentation. 
Three days after arrival, rats were familiarized with treadmill 
running on a motorized rodent treadmill by running daily for 10 
minutes at 22 meters per minute at 0% grade for four days (Farrell 
et al., 1988). After this familiarization period, animals were 
catheterized according to the procedures described by Gao et al. 
(1992). The cannulas and surgical instruments were sterilized 
overnight using sterilizing and disinfecting solutions. Animals were 
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anesthetized with ketamine (60 mg*kg~l) and xylazine (2 mg*kg~l) 
by intramuscular injection. These anesthetic agents provide 
appropriate anesthesia and analgesia and a quick recovery. The skin 
at the ventral and dorsal portions of the neck and the abdomneen 
was shaved and blotted with 70% isopropyl alcohol. A 25 mm 
longitudinal skin incision was made over the right external jugular 
vein. The vein was exposed (10 mm) and the salivary glands and 
subcutaneous tissue were moved slightly to allow placement of the 
cannula. The cannula was composed of 20 gauge polyethylene (PE 
20) tubing. A loop was made at the end of the cannula in order to 
minimize the movement of the tube in the vessel. The cannulas were 
channeled subcutaneously and through the skin on the back of the 
neck with a trocar instrument. The jugular vein was punctured with 
a 27 gauge hypodermic needle. The cannula was inserted into the 
hole and advanced 5-10 mm into the vessel. The cannula's placement 
in the vein was checked by withdrawing blood from the cannula. The 
loop of the tube was placed under the salivary glands. The cannula 
was anchored to the midline neck muscles just anterior to their 
attachement at the sternum using a 4-0 silk thread previously tied to 
the PE 20 tube. A small drop of "super glue" was applied to the 
tubing and the underlying connective tissue. The connective tissue 
beneath the skin was adhered along the midline with "super glue" 
and the skin incision was closed using a 4-0 silk thread. The outside 
portion of the cannula was connected to the skin behind the neck 
with a 2-0 silk thread. The cannulas were capped with segments (15 
mm) of a stainless steel stylet (wire). The animals received penicillin 
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(60 mg*kg"l i.m.) after the surgery and returned to their cages and 
observed until they recovered from anesthesia. The patency of the 
cannulas was maintained by daily flushing. The cannulas were 
washed with 0.2 ml of normal saline and filled with heparinized 
saline (100 U*ml~l). All surgical and cannula maintenance 
procedures were performed under aseptic conditions to reduce the 
possibility of infection. 
After the surgery animals were allowed to recover for 5 days 
and then went through a second identical familiarization running 
period. Only rats who surpassed their preoperative weight and 
demonstrated similar to preoperative weight gains were used in the 
experiments. During the first day after catheterization, most rats 
tended to lose some weight but after 2 days they started regaining 
body weight. 
Familiarization running continued after surgery for 3-6 days. 
The infusions took place 24 hours after the last bout of 
familiarization running. 
Food was withdrawn the night before, which was 7 hours before 
the commencement of an infusion. During the experiment, catheters 
were exposed for infusion. On the day of the experiment inserted 
cannulas were exposed and connected to syringes (27 gauge plastic) 
with tubing of PE 20. These syringes were connected to a Harvard 
Aparratus infusion pump. Synthetic B-EP (Sigma Chemicals, MO) was 
given by constant intravenous (right jugular vein) infusion at 0.05 
mg*kg~l*h~l after an initial intravenous bolus at 0.05 mg*kg~l. B-EP 
was dissolved in 500 ul distilled water that previously had its 
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oxygen extracted by bubbling nitrogen into the water. Then, 50 ul 
aliquots were prepared from the above solution to make 280 ul of 
0.9% saline solution. Giugliano et al. (1987), found that constant 
intravenous infusion at this dose of B-EP raised plasma 
concentrations of B-EP 7-8 fold, similar to the B-EP elevation 
observed during stress conditions such as exercise (Goldfarb et al., 
1987, 1990, 1991 ). Naloxone (Sigma Chemicals, MO) was infused 
intravenously (right jugular vein) at 0.4 mg*kg~l*hour~l after an 
initial bolus infusion (0.8 mg*kg~l). Naloxone was also dissolved in 
normal saline as B-EP. Jaffe et al. (1990), suggested that doses of 
naloxone, 0.6-0.8 mg, were able to block |i-receptors while higher 
doses can produce agonist effects. Normal saline (0.9%) was given 
intravenously (right jugular vein) at a volume equivalent to the B-EP 
volume. 
During the experimental period, animals were grouped in blocks 
of six. Each block went through the experimental stages described 
previously. 
Rats run on a motor driven treadmill (Bringham Young, Utah). 
The speed was initially set at 22 m*min~l at an elevation of 0% for 
90 minutes and then it was raised to 28 m*min~l for the last 30 
minutes in order to exhaust the animals after a total of 120 minutes. 
This type of workload represents an intensity of 60-70% of V02max 
of untrained rats (Goldfarb et al., 1981). Endurance running for two 
hours has been shown to produce a significant decline in plasma 
glucose concentration (Bergstrom et al., 1973). The rats were enticed 
to run by mild shock at the back of the treadmill. 
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Sampling 
Prior to and at 60, 90, and 120 minutes of running, six rats in 
each group were killed by decapitation and mixed venous blood 
samples were obtained. Mixed venous blood was collected into 
chilled tubes containing EDTA. Blood samples were immediately 
centrifuged (3000 RPM for 20 minutes), and plasma was collected 
and stored at -90°C until analyzed. 
Analysis of Samples 
Plasma was assayed for glucose, lactate, insulin, C-peptide, 
glucagon and B-EP. Insulin, glucagon, C-peptide and B-EP were 
analyzed by commercial radioimmunoassay kits. Glucose and lactate 
were analyzed by standard spectrophotometric procedures. 
1. Plasma Glucose. It was analyzed by an enzymatic colorimetric 
procedure which utilizes the enzymes glucose oxidase and 
peroxidase. A Sigma Diagnostics glucose kit (# 510) was used. This 
method is a modification of the procedure described by Raabo and 
Terkildsen (1960). The sample was added to a mixture containing 
glucose oxidase, peroxidase and o-dianisidine. The reaction was 
allowed to proceed to completion in approximately 30 minutes at 
37°C. The final color intensity is proportional to the glucose 
concentration. 
Glucose + 2H20 + 02 —> Gluconic Acid + 2H2O2 
H2O2 + 0-dianisidine —> oxidized o-dianisidine 
The following steps were followed: 
a) Add 10 ul of standard or unknown duplicate to tubes. 
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b) Add 1 ml of of combined enzyme - color reagent solution (500 
I.U. of glucose oxidase, 100 purpurogallin units of horseradish 
peroxidase, a buffer, 100 ul distilled water, 1.6 ml of 0-dianisidine 
solution) and mix all tubes thorougly. 
c) Incubate all tubes at 37°C for 30 minutes. 
d) Read absorbance at 450 nm. Use water and the combined 
enzyme - color reagent solution as the blank. 
e) A standard curve was drawn and the concentrations of the 
unknown samples were determined from this curve. 
2. Lactate. For the determination of lactate a standard 
spectrophotometric assay was used (Sigma kit, #826). This procedure 
is based on the convertion of L-lactate to pyruvate by lactate 
dehydrogenase (LDH) with reduction of an equivalent amount of 
NAD. The assay included the following steps: 
a) Add standards (0, 10, 20, and 30 ul) and unkowns (10 ul) to 
the corresponding labeled tubes. 
b) Add distilled water to standards (500, 490, 480, and 470 ul) 
and unknowns ( 490 ul). 
c) Add 500 ul of Glycine buffer (pH, 9.2) to all tubes. 
d) Add 25 ul of NAD to all tubes and mix. 
e) Add 5 ul of LDH to all tubes and mix. 
f) Incubate samples at room temperature for 20-30 minutes. 
g) Read absorbance ar 340 nm. The increase in absorbance at 
340 nm is proportional to lactate concentration. Unknown 
concentration were calculated from the standard curve. 
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3. Plasma Insulin. It was measured by a standard double 
antibody 125i_racji0immun0assay designed specifically for the 
quantification of plasma or serum insulin. The kit was purchased 
from ICN (CA). The procedure included the following steps: 
a) Assay was set up in duplicate in 10*75 disposable glass 
tubes. 200 ul of standards and samples were added into the tubes. 
b) Diluent bufer was added into the Non Specific Binding (NSB) 
tubes (0.4 ml), into the standards (0.2 ml) and samples (0.2 ml). 
c) Anti-insulin (antibody) (0.2 ml) was added next into all tubes 
except the NSB tubes. 
d) Next, samples and standards were mixed and incubated at 
37° C for one hour. 
e) After incubation, 0.1 ml of second antibody was added into all 
tubes. Then, samples were mixed and incubated at room temperature 
for at least one hour. 
f) After incubation, tubes were centrifuged at 2300-2500 rpm 
for 15 minutes. 
g) Then, the supernatant was decanted and the precipitates were 
counted in a gamma counter. 
4. C-peptide. It is a double-antibody 125i_radi0immun0assy. 
The kit was purchased from Linco Research Inc, (St. Louis, MO). It 
utilizes an antibody made specifically aginst rat C-Peptide. 
Sensitivity of 30 pM can be easily achieved when using a 100 (il 
palsma sample in a 2-day disequilibrium assay (400 ul total volume). 
The procedures include the following steps: 
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a) Assay buffer (300 ul) was added to the NSB tubes while 200 
ul of the same buffer were added to the 0 standard and 100 ul to the 
rest of the standards and samples. 
b) 100 ul of standards and samples were added into the tubes. 
c) 100 ul of rat C-peptide antiserum was added to all tubes 
except the NSB and total count tubes and solutions were mixed. 
d) Samples were mixed and incubated for 24 hours at 4°C. 
e) 100 ul of 125i_Rat-C-Peptide was then added to all tubes. 
f) Tubes were then mixed and incubated for 24 hours at 4°C. 
g) After incubation, 1.0 ml of precipitating reagent was added 
into all tubes. Then, samples were mixed and incubated for 20 
minutes at 4°C. 
h) Samples were then centrifuged for 15 minutes at 3000*g. 
i) The supernatant was then decanted and the precipitate was 
counted in a gamma counter. 
5. Plasma Glucagon. Total plasma Glucagon was analyzed using 
ICN plasma Glucagon RIA kit (# 07-152101). Blood was collected into 
chilled (EDTA) tubes. The assay was performed in duplicate in glass 
test tubes. Blanks, eight standards (0, 25, 50, 100, 250, 500, 1000, 
and 2000 pg*ml~l), and two controls were processed in duplicate. 
The following steps were followed: 
a) Add 0.2 ml of ultra pure water to the blanks. 
b) Add 0.2 ml of standard or unknown plasma sample to the 
tubes. 
c) Add 0.2 ml of anti-glucagon to all tubes (except blanks). 
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d) Samples will be mixed and incubated for 6 hours at 4°C ± 2. 
e) Add 0.1 ml of 125i_Giucagon to all tubes. Tubes are mixed 
and incubated at least 16 hours at 4°C ± 2. 
f) Add 0.2 ml of second antibody-PEG mixture to all tubes and 
mix. 
g) Add 1 ml of cold distilled water to all tubes. 
h) Centrifuge at 2300-2500 rpm for 15 minutes and then decant 
the supernatant. 
i) 125I in the precipitates will be counteed in a Packard gamma 
scintilation counting system for at least 2 minutes per tube. 
The average counts of all duplicate tubes were determined. The 
average blank (NSB) counts were then subtracted from the average 
counts obtained. This yields the corrected counts which are then 
divided by the corrected 0 standard counts to obtain the % bound 
(B/Bo). The % bound is then plotted vs the concentration of Glucagon 
for all standards. This yielded a standard curve. Sample values were 
then compared to this curve. The standard curve was drawn on a 
semi-log paper. 
6. Plasma B-EP. Total plasma B-EP was analyzed using INCSTAR 
plasma B-EP RIA kit (# 46065). Blood was collected into chilled 
(EDTA) tubes. The assay was conducted in duplicate in glass test 
tubes. Blanks, five standards (0, 7.1, 14.4, 29.1, 60.9, and 120.0 
pmol*l"l), and two controls were analyzed in duplicate. The whole 
procedure consisted of two steps. The first involved extraction of B-
EP from plasma using specific absorption particles. This absorbed B-
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EP was then easily and quickly eluted from the particles for 
immediate measurement in a sensitive RIA (minimum detectable 
amount is < 3 pmol*l~l). The following steps were followed: 
a) Add 0.5 ml of well-mixed suspended Sepharose particles to 
each of the chromatographic coloumns. Allow the supernatant of the 
Sepharose to drain through the coloumns. The remaining supernatant 
was forced through the columns using a rubber bulb. 
b) Tightly capped columns received 1 ml of each standard, 
control plasma, or sample 1.0 ml of 0 standard for the NSB tubes were 
used. 
c) Each column will be capped and then rotated for 4 hours at 2-
8°C in a centrifuger. 
d) Columns was placed upright in a rack . Allow the plasma to 
drain through the coloumns. A rubber bulb helped to force the 
remaining plasma through the columns. 
e) Each coloumn was washed 3 times with 0.85% saline, being 
careful to rinse both sides of the column. The columns were rinsed 
until the Sepharose is forced at the bottom of the coloumn. Force all 
remaining saline from the coloumns using the rubber bulb. 
f) Eluting of the B-EP occurred by rinsing the entire surface of 
the lower column with 250 ul of 0.025 N HCL. This exposed all the 
Sepharose parrticles to the HCL. Let stand 1 minute, then force the 
0.025 N HCL through the column into the tubes using the rubber 
bulb. This step was repeated and a total volume of 0.5 ml was 
obtained. Immediately assay the eluate according to the following 
RIA procedures. 
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g) Place a rack with 12 * 75 mm tubes on crushed ice. 
h) Add 0.2 ml of extracted standard or unknown sample in the 
labeled tubes. 
i) Add 01 ml of neutralizing buffer to all tubes except the total 
count tubes. 
j) Add 0.1 of B-EP antiserum to all tubes except the total count 
and NSB tubes. 
k) Mix the tubes without foaming and incubate for 16-24 hours 
at 2-8°C. 
1) Add 0.1 ml of 125i_b-ep to all the tubes. 
m) Mix gently without foaming and incubate for 16-24 hours at 
2-8°C. 
n) Vigorously mix the precipitating complex and add 500 ml to 
all the tubes except the total count tubes. 
o) Mix the tubes without foaming and ipcubate for 15-25 
minutes at 2-8°C. 
p) Centrifuge the tubes for 20 minutes at a minimum of 760*g at 
20-25°C. 
q) Decant the supernatant from all the tubes except the total 
count tubes and allow them to drain for a minimum time of 2 
minutes. Blot the tubes on absorbent paper to remove any drops of 
supernatant before turning the tubes upright. 
r) A Packard gamma scintilation counting system was used to 
measure the 125J in the pellet of each tube. 
The average counts of all duplicate tubes were determined. The 
average blank (NSB) counts was subtracted from the average counts 
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obtained. This yielded the corrected counts which were then divided 
by the corrected 0 standard counts to obtain the % bound (B/Bo). The 
% bound was then plotted vs the concentration of B-EP for all the 
standards. This yielded the standard curve. Sample values were then 
determined from this curve. The standard curve was drawn on a 
semi-log paper. This procedure has < 5% cross reactivity with b-LPH 
and <0.01% with a-endorphin, leucine and methionine enkephalins. 
Statistical Analysis 
A factorial, two-way Analysis of Variance (3*4 ANOVA, 
treatment by time) was performed in order to analyze the data. 
Statistical analysis did not include any repeated measures design. 
When significant interactions were noted in the 3*4 ANOVA, the 
Neuman-Keuls post-hoc procedure was used in order to clarify the 
interaction. Comparisons between groups and over time were made 
by utilizing multiple contrasts between cells. The level of significance 
was set at p < 0.05 level. All data are presented as mean ± S.E. 
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CHAPTER IV 
RESULTS 
Subject Characteristics 
The experimental design of the present study involved three 
different treatments (placebo, B-EP, and naloxone). Ninety six rats 
were initially purchased for the study. Thirteen rats were used for 
pilot work and for the practice of the surgical catheterization 
technique. Six animals in each group were sacrificed at four different 
times (0, 60, 90, and 120 min.). The desired number of at least six 
animals per treatment for each specific time examined was reached 
or even exceeded in some cases. The final sample size for the saline 
group was 26 animals, for the B-EP group was 29 animals, and for 
the naloxone groups was 28 animals. 
The means of initial and final body weights, operative weights, 
and weight gain of the rats during the experimental period are 
presented in Appendix B. The summary statistics for main effects 
obtained from the 3*4 ANOVA for these variables are also given in 
Appendix B. There were no significant differences between groups or 
times or a significant interaction effect on the animal weight 
variables (Appendix B). 
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The results of the anesthesia and the surgical techniques were 
satisfactory. The cannulation surgery lasted about 30 minutes per 
animal. There were no skin infections. The original position of the 
cannulas was maintained during the entire study. All the animals 
that underwent successful catheterization operation recovered 
completely and they were successfully infused (100% recovery rate). 
The animals' health status was monitored daily. The animals were 
considered fully recovered by their health status and by their body 
weight surpassing its preoperative value. All animals' final body 
weights were larger than the preoperative ones (Appendix B). 
In summary, animals in all groups had the same initial and final 
body weights. The rats gained similar amounts of weight as well. All 
subjects surpassed their preoperative body weight at the time of the 
experiment. Therefore, the above factors are unlikely to have 
affected the outcome of the experiment. 
Experimental Characteristics 
Animals in all three groups went through the same experimental 
stages for exactly the same amount of time as it was described in the 
methodology section (in blocks of six). All rats completed the second 
familiarization running period with no difficulty despite the fact they 
were catheterized. All animals were fasted overnight for 7 hours 
before the initiation of the infusion experiment. This manipulation 
was intended to minimize variability of carbohydrate content in the 
animals at the time of the experiment. All experimental procedures 
took place between 7.00 A.M. and 12.00 P.M. in order to avoid 
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diurnal variations of the major glucoregulatory hormones (such as 
Cortisol) and B-EP. 
Infusion pumps were calibrated before each experiment in order 
to insure an adequate delivery of the infused substances. Patency of 
the venous cannulas was maintained for all the animals throughout 
the entire study byflushing with normal saline (0.9%) daily in order 
to avoid clotting. No problems occured while the animals were 
running when they were being infused. In both the pilot and actual 
experiments, animals which were assigned to run were able to run 
for the entire 120 minutes. However, signs of exhaustion were 
obvious for animals that ran 120 minutes. Very mild electrical 
shocks were used in some instances to motivate the animals to run 
(primarily in the 120 minute run groups). In summary, no unusual 
technical problems were presented to the investigators during the 
performance of the experiments. 
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Plasma Glucose Concentrations 
The means ± S.E. for plasma glucose concentrations in the three 
groups across time are in Appendix A. Graphic representation of the 
plasma glucose data in the three groups is in Figure 5. 
A 3*4 ANOVA indicated that there were treatment, time but not 
an interaction of treatment*time main effect (p < 0.05) on plasma 
glucose concentrations (Table 7). 
Table 7. 
Summary Statistics on Plasma Glucose concentrations 
Source DF SS MS Pr > F 
Treatment 2 
Time 3 
Treat*Time 6 
Error 60 
2871.5 
54711.9 
2566.4 
11869.9 
1435.8 
18237.3 
427.7 
197.8 
7.3 
92.2 
2.2 
0.0015 
0.0001 
0.0592 
(Significance at p < 0.05) 
Plasma glucose concentration declined significantly in all groups 
across time as compared to resting values (Figure 5). More 
specifically, in the saline group, plasma glucose levels dropped 
significantly after 60 minutes of exercise, while in the other two 
groups, plasma glucose levels started declining significantly after 90 
minutes (Figure 5). In general, plasma glucose levels declined by 48% 
in the saline group, by 56% in the B-EP group, and by 45% in the 
naloxone group after 120 minutes of running compared to rest. 
88 
B-EP infusion resulted in significantly higher plasma glucose 
levels than the other two groups at 60 minutes of running. Plasma 
glucose values were still significantly higher in the B-EP group at 90 
minutes compared to the other two groups. No other significant 
differences were noted between treatments at the other times during 
exercise (Figure 5). 
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Figure 5. Plasma glucose concentration changes in the three 
groups over time. * denotes significance differences between the B-
EP group and the naloxone and saline groups (p < 0.05). 
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Plasma Lactate Concentrations 
The means ± S.E. for plasma lactate concentrations in the three 
groups across time are in Appendix A. Graphic illustration of the 
plasma lactate levels in the three groups is in Figure 6. 
There were treatment and time main effects (p < 0.05) but not 
an interaction of treatment*time effect on plasma lactate 
concentrations as indicated by the 3*4 ANOVA (Table 8). 
Table 8. 
Summary Statistics of Plasma Lactate Concentrations. 
Source DF SS MS F Pr > F 
Treatment 2 8.9 4.4 14.5 0.0001 
Time 3 18.6 6.2 20.3 0.0001 
Treat*Time 6 1.9 0.3 1.1 0.3801 
Error 60 18.3 0.3 
(Significance at p < 0.05) 
Plasma lactate concentration increased significantly in all groups 
over time compared to resting values (Figure 6). Peak plasma lactate 
concentrations were reached at 60 minutes of exercise in all groups. 
Thereafter, plasma lactate levels declined slightly but did not return 
to resting values. In general, plasma lactate concentration increased 
by 97.8% in the saline group, by 121.3% in the B-EP group, and by 
84.6% in the naloxone group (maximal lactate change during 
exercise). 
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The B-EP group had significantly higher plasma lactate levels 
than the other two groups at 60 minutes. This response was 
maintained at 90 minutes with the B-EP group plasma lactate values 
higher than the other two groups. At 120 minutes of running, B-EP 
group had higher plasma lactate levels than the saline group and 
naloxone group. No other differences between groups were detected 
(Figure 6). 
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Figure 6. Plasma lactate concentration changes in the three 
groups over time. * denotes significant differences between the B-EP 
group and the saline and naloxone groups (p < 0.05). 
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Plasma Insulin Concentration 
The means ± S.E. for plasma insulin concentration in the three 
groups across time are in Appendix A. Graphic representation of the 
plasma insulin levels is in Figure 7. 
There was a treatment and time main effects (p < 0.05) but not a 
significant interaction effect of treatment*time on plasma insulin 
concentrations as indicated by the 3*4 ANOVA (Table 9). 
Table 9. 
Summary Statistics of Plasma Insulin Concentrations. 
Source DF SS MS F Pr > F 
Treatment 2 45.0 22.5 3.7 0.0309 
Time 3 2825.0 941.6 154.3 0.0001 
Treat*Time 6 48.7 8.1 1.3 0.2577 
Error 60 366.3 6.1 
(Significance at p < 0.05) 
Plasma insulin concentration declined significantly across time 
compared to resting values in all groups (Figure 7). In general, 
plasma insulin concentration declined by 51% in the control group, 
by 50% in the B-EP group and by 57% in the naloxone group by 120 
minutes of running. 
The B-EP group had significantly lower levels of plasma insulin 
at 60 minutes of exercise compared to the other groups (Figure 7). In 
addition, the B-EP group had significantly lower plasma insulin levels 
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than the naloxone group at 90 minutes (Figure 7). No other 
significant differences in plasma insulin levels were noted between 
groups. 
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Figure 7. Plasma insulin concentration changes in the three 
groups over time. * denotes significant diferences between the B-EP 
and the saline and naloxone groups (p < 0.05). 
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Plasma C-Pentide concentration 
Plasma C-Peptide (C-P) concentration in the three groups across 
time are in Appendix A. Graphic representation of the plasma C-P 
levels is in Figure 8. 
A 3*4 ANOVA indicated that there were treatment and time 
main effects (p < 0.05) but not a significant interaction effect of 
treatment*time on plasma C-P concentrations (Table 10). 
Table 10. 
Summary Statistics of C-P Concentrations. 
Source DF SS MS Pr > F 
Treatment 2 
Time 3 
Treat*Time 6 
Error 60 
52081.4 
1661561.5 
21217.9 
1812024.9 
26040.7 
553853.8 
3536.3 
1286.1 
20.2 
430.7 
2.75 
0.0001 
0.0001 
0.0199 
(Significance at p < 0.05) 
Plasma C-P levels decreased significantly in all three groups 
with time (Figure 8). This decline was significant after 60 minutes of 
exercise and continued until the end of the run in all groups (Figure 
8). In general, C-P declined by 80% in the saline group, by 89% in the 
B-EP group, and by 82% in the naloxone group by 120 minutes of 
running. 
Multiple contrasts, following the 3*4 ANOVA for treatment 
main effects revealed that the B-EP group C-P levels were 
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significantly lower than the control and the naloxone group at 60 
minutes and 90 minutes Figure 8. No other significant differences 
between groups were detected. 
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Figure 8. Plasma C-P concentration changes in the three groups 
over time. * denotes significant differences between the B-EP group 
and the saline and naloxone groups (p < 0.05). 
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C-Peotide to Insulin Molar Ratio 
The means ± S.E. for C-Peptide to insulin molar ratio (C-P/INS) 
in the three groups across time are in Appendix A. Graphic 
representation of the C-P/INS is in Figure 9. 
A 3*4 ANOVA indicated that there were treatment and time 
main effects (p < 0.05) but not a significant interaction effect of 
treatment*time on C-P/INS (Table 11). 
Table 11. 
Summary Statistics of C-P/INS. 
Source DF SS MS F Pr > F 
Treatment 2 1.3 0.64 10.7 0.0001 
Time 3 21.9 7.32 122.0 0.0001 
Treat*Time 6 0.6 0.09 1.6 0.1603 
Error 60 3.6 0.06 
(Significance at p < 0.05) 
C-P/INS decreased significantly in all groups after 60 minutes of 
exercise and continued to decline until the end of exercise (Figure 9). 
In general, C-P/INS declined by 60.6% in the control group, by 76.3% 
in the B-EP group, and by 57% in the naloxone group by 120 minutes 
of running. 
Multiple contrasts following the 3*4 ANOVA for treatment main 
effects revealed that the B-EP group had significantly lower C-P/INS 
values than the other two groups at 90 and 120 minutes of exercise 
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(Figure 9). No other differences between groups were detected in C-
P/INS values. 
Figure 9. C-P/INS changes in the three groups over time. 
* denotes significant differences between theB-EP group and the 
saline and naloxone groups (p < 0.05). 
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Plasma Glucagon Concentration 
Plasma glucagon concentrations in the three groups across time 
are in Appendix A. Graphic representation of the plasma glucagon 
levels in the three groups is in Figure 10. 
A 3*4 ANOVA indicated that there were treatment and time 
main effects (p < 0.05) but not an interaction of treatment*time effect 
on plasma glucagon concentrations (Table 12). 
Table 12. 
Summary Statistics of Plasma Glucagon Concentrations. 
Source DF SS MS F Pr > F 
Treatment 2 283685.5 141842.8 12.8 0.0001 
Time 3 4067819.8 1355939.9 122.3 0.0001 
Treat*Time 6 63848.8 10641.5 1.0 0.4603 
Error 60 665384.3 11089.7 
(Significance at p < 0.05) 
Plasma glucagon concentration increased significantly after 60 
minutes of exercise and continued increasing until the end of 
exercise in all groups (Figure 10). In general, plasma glucagon 
concentration increased almost four fold in all groups. 
At 60 and 90 minutes, the B-EP group had significantly higher 
plasma glucagon levels than the saline and naloxone groups (Figure 
10). At 120 minutes the B-EP group had significantly higher plasma 
glucagon levels than the saline group but not compared to the 
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naloxone group. No other significant differences between treatments 
were detected. 
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Figure 10. Plasma glucagon concentration changes in the three 
groups over time. * denotes significant differences between the B-EP 
group and the saline and naloxone groups (p < 0.05). 
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Plasma B-EP Concentration 
Plasma B-EP concentrations in the three groups over time are in 
Appendix A. Graphic illustration of the plasma B-EP levels in the 
three groups is in Figure 11. 
A 3*4 ANOVA indicated that there were treatment and time 
main effects (p < 0.05) but not an interaction of treatment*time effect 
on plasma B-EP concentrations (Table 13). 
Table 13. 
Summary Statistics of Plasma B-EP Concentrations. 
Source DF SS MS F Pr > F 
Treatment 2 3901.2 1950.6 87.8 0.0001 
Time 3 10500.7 3500.2 157.6 0.0001 
Treat*Time 6 195.9 32.6 1.5 0.2038 
Error 60 1332.7 22.2 
(Significance at p < 0.05) 
Plasma B-EP concentration was raised significantly after 60 
minutes compared to rest and was further elevated at 90 and 120 
minutes in all groups (Figure 11). In general, B-EP increased five fold 
in the saline and naloxone groups and three fold in the B-EP group. 
However, all groups had increased B-EP by approximately a similar 
absolute level (25-30 pmol*l~l). 
The B-EP group maintained significantly higher levels of plasma 
B-EP than the other two groups at all times (Figure 11). There were 
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no significant differences between the saline and naloxone groups at 
any time during exercise. 
Figure 11. Plasma B-EP concentration changes in the three 
groups over time. * denotes significant differences between the B-EP 
group and the saline and naloxone groups (p < 0.05). 
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Infusion of B-EP and naloxone at rest 
In order to separate the drug effect from the exercise effect, a 
small number of animals was infused with B-EP (n = 3) or naloxone 
(n = 3) for two hours while animals were resting. The infusion rates 
were identical to the ones used during exercise. Analysis of the data 
revealed that infusion of B-EP and naloxone at rest for two hours did 
not affect any of the variables examined except for the B-EP increase 
in the B-EP group. 
Summary of the Results 
All animals which underwent catheterization surgery surpassed 
their pre-operative weight and demonstrated full recovery. No 
differences were detected between animals in different groups or 
different times on their initial and final body weights as well as on 
their weight gain. While plasma glucose declined with exercise in all 
groups, the B-EP group showed significantly higher plasma glucose 
concentrations at 60 and 90 minutes of exercise than the saline and 
the naloxone group. Plasma lactate increased significantly across all 
time periods in all groups. Plasma lactate levels were significantly 
higher in the B-EP group compared to the other two groups 
throughout the exercise period but not at rest. Plasma insulin was 
lower in all groups at each time point of exercise. Plasma insulin 
concentration was significantly lower in the B-EP group compared to 
the other two treatments at 60 minutes of exercise. At 90 minutes of 
exercise, the B-EP group had lower levels of plasma insulin than the 
naloxone group but not the saline group. Plasma C-peptide levels 
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were significantly lower at 60 and 90 minutes of exercise compared 
to time 0 in all groups, with the B-EP group demonstrating the lowest 
plasma C-P values (p < 0.05) at these two time points. C-P/INS 
declined with time in all groups and the B-EP group responded with 
the lowest values at 90 and 120 minutes (p < 0.05). Plasma glucagon 
increased with exercise in the three groups. However, the B-EP group 
had higher values at 60, 90, and 120 minutes of exercise (p < 0.05). 
B-EP concentration in plasma increased significantly during exercise 
in all groups, but as it was expected the B-EP infusion group had 
significantly higher B-EP levels at all times. 
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CHAPTER V 
DISCUSSION 
A major premise of this investigation was that prior research 
had not employed a model which involved a direct B-EP infusion 
during exercise to determine its role in glucose regulation during 
exercise. B-EP has already been documented to increase with 
exercise of sufficient duration and intensity (Goldfarb et al., 1987, 
1990). However, its role in glucoregulation could be just permissive 
rather than stimulatory. A B-EP infusion should elevate plasma B-EP 
concentration in order to amplify its actions on glucose homeostasis 
during exercise. All previous work in the area of opioid involvement 
in the regulation of substrate mobilization and more specifically in 
the regulation of glucose homeostasis during exercise, used naloxone 
infusion either in human or animal models. However, the use of 
naloxone is dubious. Despite its potential to antagonize both central 
and peripheral effects of opioids and of B-EP in particular, it has a 
non-selective receptor action. Different subclasses of opioid receptors 
may act to modulate or interact with the opioid to produce its effect. 
A non-specific blockade of the receptors with naloxone could obscure 
the significance of the opioid effect. Therefore, a direct intervention 
with B-EP infusion is needed in order to determine whether this 
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neuropeptide is involved in the regulation of glucose metabolism 
during exercise. 
A second major consideration of this study was that past 
research had not utilized a model which represented a significant 
metabolic demand. Thus, this study was designed to examine B-EP 
effects on the regulation of glucose homeostasis under what is 
considered a significant fuel mobilizing stressor. In a bout of 
prolonged duration, substrate flux and subsequent utilization 
becomes increasingly depedent upon inter-organ communication 
between muscle, liver, adipose tissue and the related hormonal 
milieu (Galbo, 1992; Romjin and Wolfe, 1992). Substrate flux and 
utilization represents a balance between availability, substrate 
utilization at the level of the exercising muscle, and the underlying 
homeostatic demand to avoid hypoglycemia. B-EP has been 
repeatedly demonstrated to increase in response to stress (Goldfarb 
et al., 1987, 1990), and as such, a regulatory implication for B-EP 
may take place under conditions that substantially tax body fuel 
supplies. A protocol of 120 minutes of prolonged running, as the one 
employed in the present study, meets these requirements (Vranic et 
al., 1976). 
Plasma Glucose Responses 
The hyperglycemic effect of morphine, a known opiate which 
acts in a similar fashion and through the same receptors as B-EP, has 
been known for many years (Araki, 1891; Feldberg et al., 1972). 
More recently, studies conducted with humans, animals or in vitro 
confirmed the hyperglycemic effect of B-EP (Feldman et al., 1983; 
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Matsumura et al., 1984). However, the major question in this study 
was if B-EP, which has been repeatedly shown to increase during 
exercise of a certain intensity and duration (Goldfarb et al., 1987, 
1989, 1990), is involved in the regulation of glucose metabolism 
during prolonged exercise and if so what functions is B-EP 
influencing? 
In contrast to the established hyperglycemic effect of B-EP at 
basal conditions, there is limited and inconclusive research on the 
involvement of B-EP on the regulation of glucose metabolism during 
exercise. Aerobic exercise of moderate intensity is a condition during 
which substrate mobilization and glucoregulatory hormone responses 
are drastically accelerated. A few studies that attempted to study the 
opioid effects on glucose homeostasis during exercise used only 
opioid antagonism with naloxone and only some of these studies 
support a role for the endogenous opioid peptides (EOP) in substrate 
mobilization during exercise (Bramnert, 1988; Farrell et al., 1986; 
Grossman et al., 1984; Staessen et al., 1985,1988). The present study 
represents the first attempt to study the opioid (B-EP) involvement 
in substrate mobilization during exercise directly by utilizing a 
continuous B-EP infusion without relying only on indirect 
observations based on opioid antagonism with naloxone. 
The present study demonstrated that there were no differences 
in the plasma glucose concentration at rest. In the present 
investigation, animals in the control group showed a significant 
decline of plasma glucose. Under most physiologic conditions, the 
rates of glucose utilization by the muscle are precisely matched on a 
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minute-to-minute basis by similar increments of glucose production 
(Vranic et al., 1976). During exercise of 60 minutes, in well trained 
animals or humans, an increased supply of glucose from the liver to 
the muscle can occur essentially without changes in the concentration 
of plasma glucose because the increased rate of glucose production 
by the liver and the increased rate of glucose utilization are 
sychronous and proportional (Vranic et al., 1969). However, our 
animals were untrained and were exercised after a 7 hour fast. In 
contrast to the control group, the B-EP and the naloxone groups did 
not demonstrate a significant decline of plasma glucose levels after 
60 minutes. Beyond the 60 minute mark, all groups demonstrated a 
significant decrease in their plasma glucose levels with time. 
Previous research has shown that prolonged exercise longer than 
60 to 90 minutes reduces plasma glucose concentration significantly 
(Galbo et al., 1976; Vranic et al., 1976). After 60 to 90 minutes of 
exercise, the need of hepatic glucose production to maintain glucose 
homeostasis is primarily influenced by continuous, peripheral 
glucose utilization. Hepatic glucose production declines eventually 
with prolongation of exercise when hepatic glycogen stores are 
depleted since the muscle continues to oxidize glucose at a constant 
rate, hypoglycemia can result. Brain hypoglycemia is presumably the 
final cause for the inability to continue prolonged physical activity 
(Issekutz et al., 1970). Thus availability of circulating glucose 
becomes a limiting factor for any sustained work performance 
(Astrand et al., 1970; Issekutz et al., 1970). 
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A major premise of this study was that in order to examine the 
opioid (B-EP) involvement in fuel utilization, a protocol of adequate 
duration should be employed. Previous attempts in the same area 
with naloxone infusion failed to detect a major counteregulatory role 
for opioids (Bramnert, 1988; Farrell et al., 1986; Grossman et al., 
1984; Staessen et al., 1988). We believe that this was in part due to 
protocols which used exercise duration shorter or up to 60 minutes. 
This kind of duration might not be an adequate stimulus for opioid 
involvement in glucose regulation. A running protocol of 120 minutes 
as the one used in the present study represents a major perturbation 
of glucose homeostasis. In one study, when a longer than 60 minutes 
exercise protocol (90 minutes) was used (Hickey, et al., 1994) opioid 
antagonism with naloxone affected glucose regulation. 
The major finding of this study is that plasma glucose levels 
were maintained significantly higher after a B-EP infusion than after 
infusion of either saline or naloxone at 60 and 90 minutes of 
exercise. This study is the first to show a hyperglycemic effect of B-
EP during exercise. The present results are in contrast with previous 
research which employed opioid antagonism with naloxone. Several 
investigators failed to show any significant alterations of 
glucoregulation when they infused their subjects with naloxone 
(Bramnert, 1988; Farrell et al., 1986; Grossman et al., 1984; Staessen 
et al., 1988). It was inferred that opioids do not play a major role in 
glucoregulation. However, their experimental protocols were 
different than the one used here. First, naloxone was infused and not 
B-EP. Second, exercise protocols were significantly different. Staessen 
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et al. (1985), showed no changes in glucoregulation during 
exhaustive graded exercise subsequent to naloxone administration. 
In another study (Staessen et al., 1988), moderate supine exercise for 
20 minutes during naloxone infusion did not change the plasma 
glucose status. Farrell et al. (1986), reported non significant increases 
in blood glucose levels during 30 minutes of exercise at 70% V02max 
on naltrexone, an opiate antagonist. 
It appears from these studies that when plasma glucose 
homeostasis is only mildly disturbed, no glucoregulatory role for the 
EOP was noted. It is also suggested from these studies that exercise 
of longer duration is probably needed to demonstrate a role for the 
EOP. In contrast to our results, Hickey et al. (1994), showed that 
opioid antagonism with naloxone caused significant elevation of 
plasma glucose during a 90 minute run (between 60 and 90 
minutes). This indicated that opioids probably work towards 
decreasing glucose levels during prolonged exercise. In the present 
study, direct opioid infusion with B-EP caused significant elevations 
of plasma glucose at 60 and 90 minutes of exercise. In addition, 
naloxone administration did not alter glucose homeostasis relatively 
to the saline group at any time during rest or exercise. This was 
similar to other studies (Staessen et al., 1988, 1985; Farrell et al., 
1986; Grossman et al., 1984). However, it must be noted that 
although the naloxone group did not have significantly higher plasma 
glucose levels than the control group, its mean plasma glucose value 
did not decrease significantly at 60 minutes as the control group. As 
in the Hickey et al. (1994) study, naloxone maintained higher plasma 
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glucose levels than the control group. However, this did not happen 
at 90 minutes of exercise where both the control and the naloxone 
groups had similar glucose levels. Furthermore, the present results 
confirm data from studies that reported a hyperglycemic effect of B-
EP infusion either centrally or peripherally during basal conditions 
(Feldman et al., 1983; Reid et al., 1981; Matsumura et al., 1984; 
Rudman et al., 1983; Borison et al., 1962; Van Loon et al., 1981). 
Naloxone failed to alter glucose homeostasis in the present 
investigation. Naloxone has been unable to block the hyperglycemic 
effect of B-EP (Feldman et al., 1983), or other B-EP effects (Rudman 
et al., 1983) as it occurred in this study. Naloxone was also unable to 
alter metabolic responses during exercise in a number of studies 
(Bramnert, 1988; Farrell et al., 1986; Grossman et al., 1984; Staessen 
et al., 1988). Despite the ineffectiveness of naloxone to inhibit B-EP 
actions peripherally, it did reverse B-EP effects centrally with or 
without concommitant central infusion of B-EP (Appel et al., 1987; 
Brown et al., 1979; Ipp et al., 1984; Van Loon et al., 1981). It seems 
that naloxone can block B-EP actions centrally but not peripherally in 
a number of studies. Therefore, the observation that naloxone did not 
affect plasma glucose levels in the present study or previous 
experiments with exercise does not necessary mean that B-EP is not 
involved in the regulation of glucose metabolism but that B-EP might 
have different pathways of action peripherally than centrally. 
Several factors could contribute to the discrepancy on the 
effectiveness of naloxone to either antagonize B-EP peripherally or 
alter glucoregulation. First, naloxone has a non-selective nature. 
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However, different subclasses of opiate receptors may act in an 
interactive fashion and a non-specific blockade may obscure the 
significance of this interaction. Second, the dose of naloxone could be 
too small relative to the B-EP concentration. It has been shown that a 
10 to 25 fold molar excess of naloxone is needed to block B-EP effects 
in animals (Rivier et al., 1977). Differences in naloxone doses could 
explain the discrepancy of research data. Farrell et al. (1986) as well 
in the present study used a dose of 0.8 mg*kg~l*h~l whereas Hickey 
et al. used 0.1 mg*kg*l*h*l. Third, some B-EP effects could be 
mediated through a non-mu-opioid receptor (Feldman et al, 1983). 
B-EP shows a great affinity for mu-receptor, the original morphine 
receptor, although it is also active at delta and epsilon receptors 
(Giugliano et al., 1988). Unlike the mu-receptor, the delta receptor is 
resistant to naloxone (Giugliano et al., 1988). Fourth, B-EP might act 
through a non-opiate pathway. Non-opiate receptors have been 
found in lymphocytes and mouse neuroblastoma cells (Gilman et al., 
1982; Hammonds et al., 1981) and these receptors are not blocked by 
opioid antagonists (Dave et al., 1985). Research also indicates the 
possibility of non-opiate binding of B-EP to Beta-adrenergic systems 
which might interact with opioid receptors (Brown et al., 1981; 
Sharma et al., 1975; Abood et al., 1985). Giugliano et al. (1989) 
showed that B-EP might interfere with cAMP in human pancreas. 
These observations suggest that B-EP may express its actions through 
receptors that are not antagonized, fully or partially, by naloxone. 
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Responses of Pancreatic Hormones 
Previous research attempted to determine whether the 
hyperglycemic effect of B-EP during basal conditions was direct or 
mediated by parallel changes in pancreatic hormone levels. Paolisso 
et al. (1987) evaluated the influence of B-EP infused at a dose similar 
to the one used here (0.05 mg*h~l) on glucose homeostasis in normal 
human subjects using the euglycaemic clamp technique. In that 
study, endocrine pancreatic function was fixed at its basal levels with 
somatostatin together with replacement of basal insulin and glucagon 
by the exogenous infusion of the hormones. In this metabolic 
condition, B-EP failed to have significant influence on the tracer-
determined glucose metabolism (production, utilization, and 
clearance). Interestingly enough, the same B-EP dose caused plasma 
glucose levels to rise when infused in humans in the abscence of the 
clamp (Paolisso et al., 1987). This seems to indicate that the 
metabolic effects of B-EP are a consequence of the changed hormonal 
"millieu" and not the expression of intrinsic metabolic properties of 
the opioid. At basal conditions, B-EP-induced hyperglycemia in 
normal subjects appears to be secondary to its stimulation on 
pancreatic hormones release. 
A. Insulin Response 
In the present study, B-EP infusion (0.05 mg*kg~l*h~l), changed 
glucose homeostasis by maintaining significantly higher plasma 
glucose levels until 90 minutes of the 120 minute run. This study 
was organized to examine if B-EP infusion was accompanied by 
simultaneous changes of pancreatic hormones as previous research at 
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basal conditions suggested. First, all groups demonstrated a 
significant decline of plasma insulin concentrations with time as 
previous research has reported (Galbo, 1981; Bloom et al., 1976; 
Issekutz et al., 1980; Martin et al., 1981). This significant decline was 
first noted at 60 minutes of exercise in the present study. Vranic et 
al. (1975) showed plasma insulin radioimmunoreactivity (IRI) 
decreases in a gradual manner during moderate exercise, while 
during strenuous exercise a near maximal decrease occurs within 
minutes after beginning running. The protocol employed in the 
present study represents a rather strenuous stress for untrained 
rats. All groups demonstrated a final insulin decline of about 50% 
over time which is not different to the 45% decline usually noted 
with strenuous exercise (Vranic et al., 1975). 
Insulin levels in plasma were lower in the B-EP group than the 
other two groups at 60 and 90 minutes of exercise. However, 
statistical significance was obtained only at 60 minutes of exercise. 
At 90 minutes, the B-EP group had statistically significantly lower 
levels of plasma insulin only compared to the naloxone group. These 
data suggest that B-EP lowers plasma insulin during exercise. There 
is limited information on how opioids affect insulin homeostasis 
during exercise. Farrell et al. (1988) found that opioid antagonism 
with naloxone had a stimulatory effect on plasma insulin during 
sustained hyperglycemia after exercise. This suggested an 
insulinopenic effect for E.O.P. Merrill et al. (1987), showed that 
insulin secretion was inhibited by naloxone after a stress. More 
recently, Hickey et al. (1994) showed that naloxone did not affect 
118 
plasma insulin levels during 90 minutes of exercise. Our results 
suggest that B-EP could act to lower plasma insulin concentration 
during exercise. This occured in conjuction with higher plasma 
glucose in the B-EP group. 
A number of studies have confirmed that opiates and opioid 
peptides may influence the secretion of the endocrine pancreas in 
different animal species (Giugliano, 1984). Experimental results, 
however, have been conflicting. Both stimulation (Reid et al., 1981; 
Feldman et al., 1983) and inhibition (Matsumura et al., 1987; 
Giugliano et al., 1989) of plasma insulin secretion has been 
demonstrated after peripheral B-EP infusion. The conflicting data is 
apparently related to the system used, the species investigated, the 
dose administered and last but not least, the concentration of glucose 
in the medium. The prevailing plasma glucose levels might alter the 
reactivity of the beta-cells to B-EP (Giugliano et al., 1988). In 
situations where plasma glucose declines as in prolonged exercise, B-
EP appears to protect glucose concentration by inhibiting insulin 
secretion (Giugliano et al., 1988). A dual, dose-depedent effect of B-
EP on insulin secretion has also been demonstrated. An i.v. bolus (50 
ug) of B-EP which produced plasma levels of more than 200-fold the 
basal values for B-EP raised plasma insulin levels, while the i.v. 
infusion (0.05 mg*h"l) raised plasma B-EP 7-8 fold and inhibited 
insulin (Giugliano et al., 1987). Literature indicates that stress such 
as exercise is associated with a 3-10 fold increase in plasma B-EP 
levels (Rossier et al., 1977; Dubois et al., 1981, Goldfarb et al., 1987). 
Our data are in agreement with these data since after continuous i.v. 
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infusion of B-EP at 0.05 mg*h~l, plasma B-EP was elevated about 8-
10 fold after 120 minutes of running and insulin was inhibited. The 
inhibitory effect of B-EP on insulin especially at 60 minutes, is 
further suggested by the failure of plasma insulin to rise in response 
to the hyperglycemia that accompanied the opioid infusion in the 
first 60 minutes. Similar findings were obtained at basal conditions 
with peripheral B-EP infusion (Giugliano et al., 1989). However, it 
must be noted here that while the control and naloxone groups 
showed a significant decrease of plasma insulin levels from 90 to 120 
minutes, the B-EP did not present the same degree of plasma insulin 
decline at this time. The fall of plasma insulin concentration from 90 
to 120 minutes of exercise was not statistically significant at the 0.05 
level. It must be mentioned, however, that the B-EP had significantly 
higher plasma glucose levels than the naloxone group and the 
control group at 90 minutes (almost 20 mg*dl~l more). It is possible 
that the higher plasma glucose levels in the B-EP group at that time 
caused this attenuated insulin response at this period of time in the 
exercise. Reactive response of insulin to the higher glucose level 
effect of B-EP has been suggested before (Reid et al., 1981). 
In the present experiment naloxone did not alter insulin 
responses. This has been demonstrated by previous exercise studies 
with naloxone infusion (Hickey et al., 1994). A few studies showed 
that naloxone infusion at normal conditions can lower plasma insulin 
levels (Locatelli et al., 1985; Schusdziarra et al., 1984; Bartolome et 
al., 1989). In contrast, others showed that naloxone infusion did not 
block the insulinopenic effect of B-EP or change pancreatic function 
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in any way (Tannenbaum et al., 1979; Rudman et al., 1983; Ipp et al., 
1984). In vitro studies demonstrated that the effects of B-EP on 
insulin secretion from rat and rabbit pancreas are not antagonized by 
naloxone (Green et al., 1983; Rudman et al., 1983). A number of 
possible reasons for the inability of naloxone to alter the effects of B-
EP were given previously. 
The large and variable hepatic extraction of insulin is a major 
obstacle to our ability to quantitate insulin secretion rates accurately. 
However, the evidence that C-peptide (C-P) is secreted from the b-
cells in equimolar concentration with insulin (Rubenstein et al 
1969; Horwitz et al., 1975), but not extracted by the liver to any 
significant degree (Stoll et al., 1970; Polonsky et al., 1981), has 
provided a firm scientific basis for the use of peripheral C-P 
concentrations as a semiquantitative marker of beta-cell secretory 
activity in a variety of situations. 
The main cause of the reduction in the plasma insulin levels 
during exercise is the supression of its secretion (Wright et al., 1969). 
Indirect measurements of decreased insulin secretion is the 
reduction in C-P concentration and in the molar ratio between C-P 
and plasma insulin (Hilsted et al., 1980; Wirth et al., 1981; 
Menshikow et al., 1983). Results from the present study agree with 
previous observations since C-P levels were significantly reduced at 
all times of exercise in all groups. 
Reasons for the decrease of C-P levels and insulin secretion 
during exercise are the fall of plasma glucose with time (Galbo et al., 
1981; Felig et al., 1979; Ahlborg et al., 1977; Bonen et al., 1977) and 
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the increase in alpha-adrenergic activity (Porte et al., 1970; Galbo et 
al., 1977,1976). 
In the belief that the hepatic extraction of C-P is negligible 
under all circumstances, peripheral C-P to insulin molar ratios have 
been assumed to reflect changes in insulin clearance. However, 
Polonsky and Rubenstein (1984) have cautioned the use of this ratio 
as an index of insulin removal. These authors have suggested that it 
is likely that alterations in the pattern and speed of equilibration of 
both insulin and C-P in their respective compartments can exert 
important influences on their relative plasma concentrations. There 
is little information on how exercise affects these parameters. 
However, recent data suggest that exercise does not alter C-P kinetics 
(Levitt et al., 1993). Another criticism is that differences in the 
plasma half lives of C-P (Sonksen et al., 1973) can further complicate 
the interpretation of the significance of changes in the C-P to insulin 
molar ratio. It is not certain how exercise influences the half-lives of 
these two peptides. 
Since there is not evidence to suggest that exercise alters C-P 
kinetics during exercise as compared to rest, the C-P to insulin molar 
ratio could be used as an indicator of insulin clearance during 
exercise. This ratio has been shown to decrease during exercise 
(Hilsted et al., 1980; Wirth et al., 1981, Brisson et al., 1971). These 
observations agree with our findings that the peripheral plasma C-P 
to insulin molar ratio (C-P/INS) was reduced significantly with time 
in all three groups suggesting a reduction of insulin clearance. This 
observation suggests that insulin clearance is reduced with exercise. 
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In contrast, in depancreatized dogs, similar or even increased insulin 
clearance (as compared to resting values) has been observed (Vranic 
et al., 1975). Reasons for this observed enhanced insulin clearance 
rate may be due to promoted binding of insulin to its receptors or 
augmented hepatic catabolism of the hormone. The discrepancy 
between this last study and the earlier-mentioned studies may be 
due to differences in relative exercise intensity or species. In 
addition, exogenous insulin was used in the later study. This 
exogenous insulin probably decreased endogenous insulin secretion, 
making calculations of clearances difficult. 
In the present study plasma C-P concentration decreased 
significantly. Additionally, C-P/INS decreased significantly as well. 
These data suggest that both insulin secretion and insulin clearance 
were reduced with exercise. However, plasma insulin concentration, 
which is the product of its secretion vs its clearance or elimination 
from the plasma, was significantly reduced with time. This means 
that the degree of reduction in insulin clearance rate was less than 
the decrease in its secretion rate. A closer examination of the results 
obtained on these two variables in the present investigation reveal 
that while C-P/INS or insulin clearance decreased by an average of 
65% in the three groups, C-P levels or insulin's secretion rate was 
reduced by an average of 85% in the three groups. 
While naloxone has been rarely found to alter insulin kinetics 
(secretion vs elimination from the plasma compartment), B-EP in this 
study appears to have an effect on these parameters. B-EP was found 
to decrease plasma insulin concentration significantly at 60 and 90 
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minutes. This observation coincided with the finding that B-EP 
suppressed insulin secretion rates as judged by plasma C-P levels. 
However, this significant depression of plasma insulin and C-P levels 
in the B-EP group as compared to the control and naloxone groups 
did not last until the end of exercise. Along with this attenuation in 
the decrease of insulin secretion after 90 minutes, a significant 
reduction of glucose removal from plasma was noted in the B-EP 
group compared to the other two groups after 90 minutes. This 
observation is based on the fact that the reduction in C-P/INS was 
similar in the three groups until 90 minutes of exercise. C-P/INS 
became significantly higher in the B-EP beyond the 90 minutes. 
Therefore, B-EP decreased plasma insulin by reducing its secretion 
until 90 minutes of exercise, but then it attenuated this reduction by 
reducing, directly or indirectly, its clearance from the plasma. This 
change could in part explain the largest decline of plasma glucose 
concentration in the B-EP after 90 minutes of exercise in the present 
study (35% drop in the B-EP group vs 14% in the other two). 
Giugliano et al. (1989) demonstrated a suppresive effect of B-EP on 
plasma insulin levels at rest. These authors, like in their earlier 
research (Giugliano et al., 1983), attributed this effect mostly on a 
depression of insulin secretion rates based on C-P levels rather than 
in changes of insulins' metabolic clearance. To a certain degree the 
present study confirms this observation since we observed that B-EP 
reduced only C-P levels before 90 minutes of exercise. However, B-EP 
effect after 90 minutes of exercise moved towards reducing 
metabolic clearance of insulin. Since prolonged exercise poses 
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different metabolic demands compared to a resting situation as in 
the Giugliano et al. (1989) study, additional factors may come into 
play. 
It is not surprising that B-EP affected plasma insulin levels in 
the present study. Early research (Ipp et al., 1978) suggested that B-
EP could alter somatostatin release from the D-cells in the pancreas. 
Somatostatin however, inhibits insulin release (Ipp et al., 1978) and 
in most cases as in the present study B-EP has been shown to 
decrease insulin release. In contrast, two in vivo experiments did not 
support a major role of somatostatin as a mediator of the B-EP effects 
on insulin release (Schusdziarra et al., 1983). A paracrine mechanism 
of B-EP action in the endocrine pancreas seems more plausible. In 
the late 70's it was shown that B-EP can be found in pancreatic cells 
(Bruni et al., 1979; Grube et al., 1980). Curry et al. (1987) later 
demonstrated that B-EP could exhibit membrane effects as opposed 
to effects on the biosynthesis of insulin. More recent observations 
(Giugliano et al., 1989) suggested that B-EP inhibits insulin release 
through a possible interaction with adrenergic receptors and cAMP. 
Another attractive hypothesis offered by Giugliano (1987) 
speculates that the prevailing glycemic state determines if B-EP will 
have a stimulatory or an inhibitory effect on insulin secretion. It 
could be that B-EP stimulates insulin when hyperglycemia was 
observed in studies using a glucose challenge or obese subjects 
(Khawaja et al., 1990; Locatelli et al., 1985) and B-EP inhibits insulin 
release in situations where plasma glucose tends to decline such as in 
exercise. 
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B, Glucagon response 
The glucagon content of plasma increases gradually during 
exercise (Vranic et al., 1975; Felig et al., 1972; Issekutz et al., 1980). 
This change is found to be depedent on both intensity and duration 
of the exercise (Galbo et al., 1975). A strenuous protocol of long 
duration, especially with untrained subjects, as the one used in this 
study, has been found to elicit a significant increase of plasma 
glucagon (Vranic et al., 1975; Winder et al., 1978). An important 
peculiarity of blood glucagon response is the lag period from the 
onset of exercise until the appearance of a rise in its concentration. 
At the level of 50-70% of V02max, the time of rise in plasma 
glucagon is 45-60 minutes (Luyckx et al., 1978; Winder et al., 1978). 
This time is thought to be a species-depedent phenomenon. In man it 
is well pronounced, but in rats and sheep an increase in plasma 
glucagon levels can be seen immediately at the onset of the exercise 
(Galbo, 1981; Winder et al., 1979). Our findings agree with these 
earlier observations since plasma glucagon concentration was 
significantly increased after 60 minutes of exercise and kept 
increasing until the end of the run in all three groups. This increase 
in plasma glucagon is believed to occur primarily due to a fall in 
blood glucose levels (Galbo et al., 1977). The effect of the fall in 
plasma glucose can either be direct on pancreatic alpha-cells (Muller 
et al., 1972) or indirect by causing sympathetic stimulation (Richter 
et al., 1980). In rats alpha-adrenergic stimulation is more significant 
(Richter et al., 1980). However, even during prolonged exercise, 
increments in catecholamine levels cannot fully account for the rise 
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in glucagon concentration (Galbo et al., 1975). 
Despite the fact that studies performed at rest consistently noted 
a stimulation of alpha-cell secretion of glucagon (Giugliano et al., 
1989; Reid et al., 1981; Feldman et al., 1983; Matsumura et al., 1984; 
Paolisso et al., 1987;Schleicher et al., 1987), even during a glucose 
challenge (Giugliano et al., 1989), studies that utilized an exercise 
model with naloxone infusion did not show any significant effects on 
glucagon levels (Grossman et al., 1984; Hickey et al., 1994). 
Variability in exercise protocols could in part explain these results. 
At all times during exercise, B-EP infusion elevated plasma glucagon 
levels at a significantly higher degree compared to the other two 
groups in the present study. This is the first study to demonstrate 
that B-EP stimulates glucagon secretion during exercise. On the other 
hand, naloxone did not alter glucagon metabolism during exercise as 
in previous studies (Grossman et al., 1984; Hickey et al., 1994). 
Possible explanations as to why naloxone was unable to alter 
glucagon response and other variables involved in the regulation of 
glucose homeostasis have been given previously. Whether the effects 
of B-EP (on insulin and glucagon) reflect a direct action on the 
pancreas or a centrally mediated process indirectly requires further 
studies. However, B-EP is known to influence the pancreatic 
hormonal secretion in vitro (Giugliano et al., 1984), and therefore, it 
seems conceivable that its effects on peripheral insulin and glucagon 
concentrations represent the result of the impact on a- and b-cell 
secretion. Furthermore, B-EP has been shown to be localized in 
pancreatic cells (Bruni et al., 1979; Grube et al., 1980). 
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Plasma Lactate Response 
Blood lactate concentration increased after 45-60 minutes of 
prolonged exercise of submaximal intensity (Pruett et al., 1970; Galbo 
et al., 1977) and then (90-120 minutes) this rise subsides while it is 
still higher than resting levels (Galbo et al., 1977; Winder et al., 
1982). This later decrease in blood lactate accumulation has been 
found to be due to its increased removal and use for gluconeogenic 
pathways at later stages of prolonged exercise (Brooks, 1985). Our 
results on plasma lactate agree with previous observations since 
plasma lactate increased significantly after 60 minutes and remained 
higher than resting levels throughout the exercise period in all three 
groups. 
Lactate is a product of glycogenolysis and glycolysis. The 
intracellular enzymes which process carbohydrates produce lactic 
acid as a function of their metabolism. This is because the terminal 
enzyme of the glycolytic pathway lactate dehydrogenase (LDH) has 
the greatest catalytic activity (Vmax) of any glycolytic enzyme 
(Brooks, 1985). Additionally, the catalytic activity of LDH exceeds by 
many times the combined catalytic activities of enzymes involved in 
alternative pathways for pyruvate metabolism (Everse et al., 1973; 
Karlsson et al., 1974). Therefore, substrate levels of pyruvate are 
enough to support maximal catalytic activity of LDH for the 
production of lactate, during exercise. 
In the present experiment, B-EP was found to elicit significantly 
higher concentration of lactate in the plasma as compared to the 
other two groups while naloxone had similar values to the saline 
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group. De Meirleir et al. (1986), noticed that at exhaustion, B-EP 
levels increased parallel to lactate values. Studies describing 
correlations between B-EP and lactate (Buono et al., 1987; Farrell et 
al., 1983) assumed that substances from anaerobic metabolism could 
stimulate the hypothalamus-pituitary axis via chemoreceptors in the 
muscle. This speculation seems to agree with observations which 
suggest that B-EP increased glycogenolysis and gluconeogenesis from 
L-lactate (Allan et al., 1983; Matsumura et al., 1984). 
In the present investigation B-EP caused a significant rise in 
plasma glucose concentration until 90 minutes of exercise. Increased 
plasma glucose levels could have increased the glucose uptake by the 
muscle. This in turn could enhance glucose flux into the working 
muscle. Since lactate is formed as a result of the glycogenolytic and 
glycolytic pathways, accelerated flux might have occurred in the 
present study. Therefore, LDH would see higher substrate levels 
resulting in increased muscle lactate production and inevitably more 
plasma lactate would appear. Finally, circulating concentrations of 
lactate reflect a balance between two opposing processes; production 
and removal. Any aspect of either production or removal, including 
redox buffering, alterations in regional blood flow and/or alterations 
in the hormonal millieu, could contribute to transient changes in 
lactate concentration. It is unclear as to the exact mechanism for the 
elevated lactate. 
Plasma B-EP Response 
It is well substantiated that plasma B-EP increases with exercise 
of adequate intensity and duration (Goldfarb et al., 1987,1990, 
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1991). The results in all three groups of this study confirm this 
notion. B-EP in plasma increased gradually in all groups with the 
highest levels obtained at 120 minutes. As it was expected, plasma 
B-EP was significantly elevated in the B-EP infused group compared 
to the other two groups at all times. The naloxone group had plasma 
B-EP values similar to the saline group's. 
There is no information from previous research on the 
pharmakonetics of B-EP, its compartmental distribution or its half 
life during exercise. Nevertheless, when B-EP was infused at a 
continuous fashion and at a same dose as ours, plasma B-EP 
concentration increased 7-8 fold (Giugliano et al., 1987). In the 
present study, plasma B-EP concentration increased 7 fold above 
rest. 
Possible mechanisms on how B-EP affects glucose regulation 
during exercise 
Plasma glucose concentration reflects only the balance between 
the rate of glucose production or appearance and the rate of glucose 
clearance or uptake of glucose by peripheral tissues. Working 
skeletal muscle and the brain are the main tissues that utilize glucose 
during exercise (Vranic, 1975). Therefore, the hyperglycemic effect 
of B-EP during exercise observed in this study and at rest in previous 
studies could be attributed to either an increase in its appearance, a 
decrease in its disappearance or both. It has been shown that glucose 
production rather glucose utilization is more likely to be stimulated 
by either a central (Radosevich et al., 1989; Nush et al., 1989) or 
peripheral B-EP infusion (Matsumura et al., 1984; Allan et al., 1983; 
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Leach et al., 1985). However, two other studies could not confirm 
these results (El Tayeb et al., 1985; Brubaker et al., 1987). 
If B-EP stimulates glucose production, then this could be 
achieved through only two pathways; hepatic glycogenolysis and/or 
gluconeogenesis from various substrates such as lactate, amino acids 
and glycerol. Opioid peptides have been shown to induce 
glycogenolysis in the liver and this effect was cAMP related (Allan 
et al., 1983; Matsumura et al., 1984). However, no changes in 
glycogen phosphorylase-a activity after B-EP addition in rat 
hepatocyte medium was noted (Brubaker et al., 1987). 
B-EP was able to stimulate gluconeogenesis as well in liver from 
L-lactate (Matsumura et al., 1984). Lactate concentration in plasma 
was significantly increased in the plasma in the B-EP group in the 
present study. The glycogenolytic control process during exercise is 
multifactorial. It appears to be primarily regulated by the combined 
drop in insulin and increase in glucagon (Farrell, 1992; Galbo et al., 
1992; Kjaer et al., 1987; Wasserman et al., 1992). Wasserman et al. 
(1992), have shown that the effect of the fall in insulin is to relieve 
the inhibition of hepatic glycogenolysis, and that this can account for 
as much as 65% of the increased hepatic glucose output. In addition, 
the fall in insulin sensitizes hepatic tissue to glucagon, such that the 
same absolute level of this hormone elicits a more potent response 
(Wasserman et al, 1992). It has been found that the elevation in 
glucagon primarily increases hepatic gluconeogenic efficiency, and 
that this accounts for almost 40% of the rise in hepatic glucose output 
(Farrell, 1992; Galbo, 1992; Kjaer et al., 1987). Our results confirm 
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these observations. Plasma glucose increased significantly in the B-EP 
group at a time when plasma insulin and C-P decreased and glucagon 
increased compared to the other two groups. This also agrees with 
the significant shift towards glucagon in the B-EP group at 60 and 90 
minutes based on the glucagon to insulin molar ratio in plasma 
(GLU/INS). Other counteregulatory hormones such as catecholamines 
(CATS), Cortisol and growth hormone can contribute to hepatic 
glycogenolysis and gluconeogenesis (Vranic et al., 1979) but their 
measurement was beyond the scope of this study. B-EP has been 
shown to stimulate (Feldberg, 1974; Van Loon et al., 1985) and 
inhibit CATS (Tannenbaum et al., 1979). Naloxone studies with 
exercise increased CATS (Farrell et al., 1991; Hickey et al., 1994; 
Grossman et al., 1984). Data concerning Cortisol and growth hormone 
responses to naloxone and not B-EP administration during exercise is 
equivocal. The majority of the investigations suffer from the limited 
duration problem indicated previously. Cortisol and growth hormone 
have been shown to exert metabolic actions after 90 minutes of 
exercise (Vranic et al., 1979). 
Another possibility for the B-EP-induced hyperglycemia during 
exercise, is an decreased utilization of glucose by the working 
muscles. Eventhough our data can not support this claim, it has been 
shown that B-EP can have a lipolytic effect on adipose tissue at rest 
(Richter et al., 1983) and during exercise (Vettor et al., 1987). 
Increased utilization of fatty acids during prolonged exercise can 
spare glucose utilization (Vranic et al., 1979). However, the increased 
plasma lactate concentrations with B-EP infusion observed in this 
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study, support a higher glycolytic flow. 
After 90 minutes of exercise plasma glucose declined at a higher 
degree in the B-EP group (35%) compared to the other two groups 
(14% each). At the same time, C-P/INS and GLU/INS decrease was 
significantly attenuated in the B-EP group compared to the other 
groups, indicating a lower insulin clearance. A secondary rise in 
insulin can result in hypoglycemia at basal conditions (Reid et al., 
1981). Chronic opioid administration has been associated with a 
paradoxical hypoglycemia and hyperinsulinism (Schmid et al., 1953; 
Reed et al., 1973). This could contribute to a higher plasma glucose 
uptake by the muscle after 90 minutes. Vranic et al. (1975) showed 
that even limited amounts of circulating insulin are enough to 
stimulate muscle glucose uptake due to the increased blood flow with 
exercise. Another explanation could be that higher liver 
glycogenolysis occurred in the B-EP group. However, liver glycogen 
was not measured in this study. 
In summary, B-EP was found to cause an elevation of plasma 
glucose at 60 and 90 minutes of a prolonged bout of exercise lasting 
120 minutes. This effect seems to be due to B-EP impact on the 
function of the endocrine pancreas by reducing insulin secretion and 
stimulating glucagon release. These results suggest that B-EP could 
be involved in the glucoregulatory mechanism during prolonged 
exercise. However, further research is needed in order to determine 
the mechanism(s) of its action. 
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CHAPTER VI 
CONCLUSIONS AND RECOMMENDATIONS 
Our initial null hypothesis stated that B-EP infusion will not 
affect glucose homeostasis during exercise and the underying 
changes in the counterregulatory hormones. This hypothesis was 
rejected after analysis of the data obtained in this study. B-EP has 
been shown to yield elevations in plasma glucose concentration 
during a bout of prolonged exercise. Specifically, B-EP maintained 
higher plasma glucose levels than during a control situation at 60 
and 90 minutes of a prolonged run which lasted 120 minutes. This 
effect of B-EP was seen at a time when plasma insulin and glucagon 
responses were significantly modified by B-EP. The infusion of the 
opioid resulted in a substantial decline of insulin release and a 
synchronous significant increase of plasma glucagon at 60 and 90 
minutes of exercise. Thus, it appears that the hyperglycemia 
manifested by B-EP infusion was mediated by the B-EP effects on 
insulin and glucagon metabolism. In addition, a higher plasma lactate 
concentration was seen with B-EP infusion, possibly due to a higher 
glycolytic flow in the working muscle. Nevertheless, this 
hyperglycemic effect of B-EP during the first 90 minutes of running 
was followed by a larger drop of plasma glucose in the last 30 
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minutes of exercise. This effect was accompanied by a simultaneous 
reduction of plasma insulin clearance. 
Naloxone did not influence either glucose homeostasis or the 
counteregulatory hormones during exercise at all times. It might be 
that the effects of B-EP on glucose metabolism and substrate 
utilization are expressed through cellular pathways that can not be 
blocked by naloxone. 
Our results confirm previous research findings from studies 
performed at rest that B-EP elicits hyperglycemia through its effects 
on major glucoregulatory hormones such as insulin and glucagon. 
However, the exact cellular mechanism(s) of such action by B-EP are 
not currently known and they were beyond the scope of this study. 
Therefore, the investigators can offer the following recommendations 
for future research in this field: 
1. Substrate mobilization was assessed indirectly in this study 
by looking at plasma glucose and lactate. The effects of B-EP on the 
utilization of liver and muscle glycogen, the oxidation of fats can be 
measured in the future in order to determine fuel interelationship 
and how it is affected by B-EP. This could account for the observed 
hyperglycemic effect of B-EP. Tracer methodology could be 
extremely valuable in this case. 
2. The effects of B-EP on CATS, Cortisol and growth hormone 
were not exemined in this study. These hormones and especially 
CATS are known to influence glucose homeostasis during prolonged 
exercise. CATS interaction with the pancreatic hormones and their 
effects on muscle glycogenolysis and adipose tissue lipolysis could 
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help to answer questions on the mechanisms of B-EP actions. 
3. Investigation of B-EP infusion effects during a pancreatic 
clamp at exercise with somatostatin. This manipulation would allow 
to examine if B-EP effects on glucose homeostasis during exercise are 
secondary to changes in the pancreatic hormones. 
4. The effects of B-EP in humans should be assessed in order to 
examine if this B-EP effects on glucose metabolism are species 
related phenomena. 
5. Work with animal models suggests that central and peripheral 
levels opioid systems are indepedently regulated, and that elevations 
in peripheral levels can not be taken as an indication of concomitant 
central responses (Sforzo et al., 1985). Therefore, it is recommended 
that future research should examine how a central B-EP infusion 
during exercise affects glucose metabolism peripherally. 
6. Exercise constitutes a stress condition where glucose 
homeostasis can be drastically disturbed. It is important to 
investigate if B-EP is involved in the counterregulatory mechanism 
during other situations where disturbance of glucose metabolism is 
also observed; namely, diabetes and obesity. 
7. Different dosages of B-EP and naloxone should be used. Very 
little is known about the pharmacokinetic behavior of these agents 
during exercise. 
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APPENDIX A 
(Raw Data and Descriptive Statistics of the Depedent Variables) 
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GROUP TIME ID GLUC LAC INS C-P C-P/IN GLU B-EP 
1 133.6 1.27 32 483 2.26 250 7.0 
1 1 2 142.7 1.18 33 400 1.81 185 9.0 
1 1 3 139.8 1.05 40 520 1.95 180 11.0 
1 1 4 123.8 1.66 29 480 2.48 170 5.0 
1 1 5 133.5 1.19 31 360 1.74 140 6.0 
1 1 6 128.0 1.26 27 500 2.77 180 8.0 
1 2 1 116.7 1.89 23 240 1.57 300 18.0 
1 2 2 97.6 2.40 25 210 1.26 260 21.0 
1 2 3 94.2 2.65 23 180 1.17 320 22.0 
1 2 4 125.8 2.88 25 210 1.26 320 22.0 
1 2 5 130.9 3.36 25 190 1.14 300 24.0 
1 2 6 99.8 2.51 26 270 1.55 330 19.0 
1 3 1 95.5 1.72 20 120 0.90 460 27.0 
1 3 2 80.6 1.31 21 140 1.00 480 29.0 
1 3 3 68.5 4.03 21 140 0.99 390 29.0 
1 3 4 79.8 1.59 22 115 0.78 330 26.0 
1 3 5 96.5 1.52 22 105 0.71 400 31.0 
1 3 6 69.4 1.68 18 160 1.33 410 28.0 
1 4 1 69.7 2.11 16 115 0.89 1100 38.8 
1 4 2 76.6 2.26 16 100 0.93 740 41.0 
1 4 3 83.3 2.03 14 105 1.12 820 34.0 
1 4 4 54.9 1.71 15 110 1.10 420 34.0 
1 4 5 55.9 1.32 17 80 0.70 720 39.0 
1 4 6 78.5 1.36 17 75 0.66 580 43.0 
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2 1 1 145.4 1.02 31 500 2.07 210 15.0 
2 1 2 126.3 1.67 36 400 1.67 260 21.0 
2 1 3 161.2 1.82 32 500 2.34 250 17.0 
2 1 4 152.0 1.88 32 460 2.15 250 20.0 
2 5 157.5 1.48 27 400 2.22 440 12.0 
2 1 6 142.1 1.55 32 480 2.25 150 22.0 
2 2 1 139.8 2.64 24 115 1.22 420 36.0 
2 2 2 167.5 3.22 19 150 1.18 500 37.0 
2 2 3 121.8 4.06 20 110 1.22 460 39.0 
2 2 4 164.1 3.86 24 100 1.02 300 34.0 
2 2 5 128.6 2.83 20 125 0.93 480 36.0 
2 2 6 131.6 3.35 22 100 1.18 440 38.0 
2 3 1 99.3 2.59 18 70 0.58 520 40.0 
2 3 2 86.9 2.81 20 50 0.37 700 43.0 
2 3 3 112.6 3.18 18 60 0.50 640 45.0 
2 3 4 79.3 3.09 20 30 0.22 640 47.0 
2 3 5 124.6 3.19 17 60 0.53 600 40.0 
2 3 6 96.1 3.32 17 50 0.44 600 47.0 
2 4 1 56.2 2.09 17 40 0.35 1100 58.0 
2 4 2 50.5 2.90 15 55 0.55 942 60.0 
2 4 3 61.2 3.65 17 30 0.26 1100 82.0 
2 4 4 62.3 2.57 13 80 0.92 850 46.0 
2 4 5 75.8 3.56 14 60 0.64 840 43.0 
2 4 6 81.4 2.89 18 30 0.25 820 57.0 
2 5 1 - 3.42 - 350 - 270 -
2 5 2 147.4 2.56 33 380 2.03 240 43.0 
2 5 3 127.4 3.13 
2 5 4 148.4 3.80 
3 1 1 132.2 1.13 
3 1 2 133.0 1.21 
3 1 3 120.9 1.55 
3 1 4 136.2 1.09 
3 1 5 130.1 1.42 
3 1 6 143.5 1.74 
3 2 1 84.5 1.55 
3 2 2 140.2 3.01 
3 2 3 126.7 2.89 
3 2 4 143.3 3.22 
3 2 5 102.3 2.23 
3 2 6 118.1 1.54 
3 3 1 68.6 2.07 
3 3 2 82.7 3.56 
3 3 3 99.2 1.91 
3 3 4 80.4 1.81 
3 3 5 93.7 2.12 
3 3 6 70.0 1.49 
3 4 1 71.2 2.90 
3 4 2 78.3 2.10 
3 4 3 60.0 1.78 
3 4 4 85.7 2.47 
3 4 5 79.9 2.64 
3 4 6 58.3 1.81 
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340 1.75 250 45.0 
350 2.18 - 40.0 
460 2.13 200 11.0 
440 1.94 210 5.0 
460 1.81 230 5.0 
400 1.87 200 7.0 
600 2.23 150 10.0 
460 2.55 150 5.0 
250 1.50 200 18.0 
260 1.62 400 18.0 
220 1.37 420 23.0 
190 1.24 280 20.0 
210 1.26 280 21.0 
180 1.04 390 21.0 
110 0.72 500 28.0 
135 0.96 560 27.0 
160 1.26 550 27.0 
150 1.07 270 28.0 
120 0.75 400 30.0 
120 0.81 560 26.0 
60 0.56 820 37.0 
110 1.37 950 37.0 
87 1.20 750 42.0 
90 0.66 1100 35.0 
89 0.64 800 35.0 
85 1.04 760 33.0 
29 
34 
32 
34 
38 
32 
40 
27 
25 
24 
24 
23 
25 
26 
23 
21 
19 
21 
24 
22 
16 
12 
15 
17 
14 
13 
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3 5 1 163.8 1.65 27 82 2.55 220 12.0 
3 5 2 143.9 1.71 37 78 2.22 390 5.0 
3 5 3 151.1 1.76 34 72 1.60 220 11.0 
- Group 1 is the saline group, group 2 is the B-EP group, and 
group 3 is the naloxone group. 
- Times 1, 2, 3, 4 denote 0, 60, 90, 120 minutes of exercise. 
Time 5 represents the 120 minute infusion of B-EP and naloxone at 
rest. 
- GLUC is the plasma glucose concentration (mg/dl). 
- LAC is the plasma lactate concentration (mM). 
- INS is the plasma insulin concentration (ulU/ml). 
- C-P is the plasma C-peptide concentration (pM). 
- C-P/INS is the C-peptide to insulin molar ratio in the plasma. 
- GLU is the plasma glucagon concentration (pmol/1). 
- B-EP is the plasma beta-endorphin concentration (pmol/1). 
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Means + S.E. for Plasma Glucose Concentrations in all Three Groups 
Across Time. 
TIME Saline Group B-EP Group Naloxone Group 
0 Min. 133.6 ±3.5 
(N-6) 
147.4 ±5.6 
(N=6) 
132.6 ±3.1 
(N-6) 
60 Min. 110.8C ± 6.4 
(N-6) 
142.2a ±7.7 
(N-6) 
119.2b ±9.2 
(N-6) 
90 Min. 81.7C,d + 4.9 
(N-6) 
99.8a,c,d ± 6.8 
(N-6) 
82.4b, c,d + 5.9 
(N-6) 
120 Min. 69.8C ± 4.9 
(N-6) 
64.6c>e ± 4.8 
(N-6) 
72.2C ± 4.5 
(N-6) 
(Glucose concentration is in mg/ dl, a denotes a significant 
difference between the saline and B-EP groups, b denotes a 
significant difference between the B-EP and naloxone groups, c 
denotes values significantly different from rest, d denotes a 
significant difference between 60 and 90 minutes, e denotes a 
significant difference between 90 min. and 120 minutes) 
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Means + S.E. for Plasma Lactate Concentrations in all Three Groups 
Over Time. 
TIME Saline Group B-EP Group Naloxone Group 
OMin. 1.26 ±0.09 
(N-6) 
1.57 ±0.12 
(N-6) 
1.35 ±0.10 
(N-6) 
60 Min. 2.61C + 0.20 
(N-6) 
3.32a>c ± 0.22 
(N=6) 
2.40b>c ± o.30 
(N-6) 
90 Min. 1.97C,d ± o.41 
(N-6) 
3.03a>c ± 0.11 
(N-6) 
2.16^ + 0.29 
(N-6) 
120 Min. 1.72C + 0.13 
(N-6) 
2.94a,c ± 0.24 
(N-6) 
2 .28b,c±o. l8 
(N-6) 
(Lactate concentration is in mM, a denotes significant difference 
between the saline and B-EP groups, b denotes significant difference 
between the B-EP and naloxone groups, c denotes values significantly 
different from rest, d denotes significant difference between 60 and 
90 min.) 
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Means + S.E. for Plasma Insulin Concentrations in all Three Groups 
Over Time. 
TIME Saline Group B-EP Group Naloxone Group 
0 Min. 32.0 ± 1.71 
(N=6) 
31.6 ± 1.16 
(N=6) 
33.8 ± 1.73 
(N=6) 
60 Min. 24.5C ± 0.49 
(N=6) 
21.5a>c + 0.88 
(N=6) 
24.5b,c ± 0.42 
(N=6) 
90 Min. 20.6c>d± 0.61 
(N=6) 
18.3C,d + 0.55 
(N=6) 
2i.6b,c,d±o.71 
(N=6) 
120 Min. 15.8c,e ± 0.43 
(N=6) 
15.6C + 0.80 
(N=6) 
14.5C,e ± 0.76 
(N=6) 
(Insulin concentration is in mlU/ ml, a d lenotes significant 
difference between the saline and B-EP group, b denotes significant 
difference between the B-EP and naloxone group, c denotes 
significant different from rest, d denotes significant difference 
between 60 and 90 min., e denotes significant difference between 90 
and 120 min.) 
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Means t S.E. for Plasma C-Pepticte Concentrations in all Three Groups 
Over Time, 
TIME Saline Group B-EP Group Naloxone Group 
0 Min. 457.2 ±40.1 
(N=6) 
456.7 ±22.1 
(N=6) 
470.0 ±24.4 
(N=6) 
60 Min. 216.6C ± 13.5 
(N=6) 
116.7a,c ± 7.7 
(N=6) 
218.3b,c± 12.9 
(N=6) 
90 Min. 130.0^4 ± 8.2 
(N=6) 
53.3a,c,d ± 5.5 
(N=6) 
132.5h,c,d±7.9 
(N=6) 
120 Min. 97.5C ± 5.7 
(N=6) 
49.2C + 8.0 
(N=6) 
85.8C+ 10.3 
(N=6) 
(C-P concentration is in pM, a denotes significant difference between 
the saline and B-EP group, b denotes significant difference between 
the B-EP and naloxone group, c denotes means significant different 
from rest, d denotes significant difference between 60 and 90 min) 
183 
Means + S.E. for C-P/INS in all Three Groups Over Time. 
TIME Saline Group B-EP Group Naloxone Group 
OMin. 2.16 + 0.19 
(N=6) 
2.11 ±0.11 
(N=6) 
2.09 ±0.11 
(N=6) 
60 Min. 1.32C ± 0.07 
(N=6) 
1.12C+ 0.04 
(N=6) 
1.33C ±0.08 
(N=6) 
90 Min. 0.95C,d ± 0.O8 
(N=6) 
0.44a,c,d ± o.04 
(N=6) 
0.93b,c,d ± 0.O8 
(N=6) 
120 Min. 0.90c ± 0.07 
(N=6) 
0.49a,c + 0.10 
(N=6) 
0.9lb,c + 0.13 
(N=6) 
(a denotes significant difference between the saline and B-EP group, 
b denotes significant difference between the B-EP and naloxone 
group, c denotes means significant different from rest, d denotes 
significant difference between 90 and 120 min) 
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Means + S.E. for Plasma Glucagon Concentrations in all Three Groups 
Over time, 
TIME Saline Group B-EP Group Naloxone Group 
0 Min. 184.2 ± 12.9 
(N=6) 
243.3 ± 33.4 
(N-6) 
190.0 ± 11.3 
(N-6) 
60 Min. 305.0C+ 10.2 
(N-6) 
433.3a>c + 29.0 
(N-6) 
308.3b,c±35.8 
(N-6) 
90 Min. 411.6C +21.8 
(N=6) 
616.6a>c>d ± 24.4 
(N-6) 
473.3b, c,d + 56.6 
(N-6) 
120 Min. 730.0c>e + 87.5 
(N-6) 
942.0a,c,e ± 59.0 
(N-6) 
863.3c»e + 55.6 
(N-6) 
(Plasma glucagon concentration is in pg/ ml, a denotes significant 
difference between the B-EP and saline groups, b denotes significant 
difference between the B-EP and naloxone groups, c denotes values 
significantly different from rest, d denotes significant difference 
between 60 and 90 min. times, e denotes significant difference 
between 90 and 120 min. times) 
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Means + S.E. for Plasma B-EP Concentrations in the Three Groups Over 
Time. 
TIME Saline Group B-EP Group Naloxone Group 
OMin. 7.7 ± 0.89 
(N=6) 
17.8a ± 0.99 
(N=6) 
7.2b ± 1.03 
(N=6) 
60 Min. 21.0C ± 0.89 
(N=6) 
36.7a>c + 0.71 
(N=6) 
20.2b,c + 0.79 
(N=6) 
90 Min. 28.4c»d + 0.79 
(N=6) 
43.6a,c,d±  i.30 
(N=6) 
27.6b,c,d ± 0.61 
(N=6) 
120 Min. 38.3C,e± 1.50 
(N=6) 
57.6a, c,e + 6.28 
(N=6) 
36.5b,c,e+ 1.25 
(N=6) 
(Plasma B-EP concentration is in pmol/ ml, a denotes significant 
difference between the B-EP and saline groups, b denotes significant 
difference between the B-EP and naloxone groups, c denotes values 
significantly different from rest, d denotes significant difference 
between 60 and 90 minutes, e denotes significant difference between 
90 and 120 minutes) 
APPENDIX B 
(Raw Data and Statistics of Animals' Weights) 
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GROUP TIME I.D. I.W. O.W. F.W. W.G. 
1 1 1 201 254 260 59 
1 1 2 214 311 323 109 
1 1 3 204 288 306 102 
1 1 4 211 308 308 97 
5 221 295 318 97 
1 1 6 218 291 303 85 
1 1 7 212 278 288 76 
1 2 1 228 270 280 52 
1 2 2 216 290 298 82 
1 2 3 208 290 305 97 
1 2 4 208 283 293 85 
1 2 5 209 271 295 86 
1 2 6 215 278 301 86 
1 3 1 201 275 299 98 
1 3 2 208 295 300 92 
1 3 3 204 318 328 124 
1 3 4 219 294 294 75 
1 3 5 205 277 295 90 
1 3 6 210 292 299 89 
1 4 1 220 239 254 34 
1 4 2 201 269 278 77 
1 4 3 205 271 291 86 
1 4 4 210 276 291 81 
1 4 5 212 284 292 80 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
188 
4 
4 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
6 214 286 298 84 
7 218 265 283 65 
1 210 225 262 52 
2 217 300 318 101 
3 201 277 311 110 
4 206 274 288 82 
5 213 295 305 92 
6 204 275 305 101 
7 221 282 301 80 
1 212 270 295 83 
2 208 306 328 120 
3 220 278 290 70 
4 203 282 295 92 
5 210 283 300 90 
6 220 301 315 95 
1 207 314 315 108 
2 201 285 294 93 
3 210 282 290 80 
4 220 290 306 86 
5 211 269 289 78 
6 221 277 302 81 
1 205 290 308 103 
2 211 278 299 88 
3 204 305 324 120 
4 221 279 310 89 
5 212 277 304 92 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
189 
4 
5 
5 
5 
5 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
4 
4 
6 212 280 301 89 
1 217 256 256 39 
2 210 313 323 113 
3 213 213 305 92 
4 208 208 291 83 
1 224 242 250 26 
2 206 306 308 102 
3 202 285 314 103 
4 211 285 302 94 
5 208 297 310 103 
6 207 306 320 118 
7 215 275 286 71 
1 206 265 290 84 
2 209 275 294 85 
3 204 288 299 95 
4 204 301 309 105 
5 224 285 300 76 
6 208 286 309 101 
1 210 293 308 98 
2 200 295 298 98 
3 215 233 266 51 
4 208 290 302 94 
5 209 285 302 93 
6 211 291 309 98 
1 218 314 343 125 
2 216 286 301 85 
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3 4 3 204 273 291 87 
3 4 4 209 286 299 90 
3 4 5 210 293 299 89 
3 4 6 2J8 292 303 85 
3 5 1 218 293 300 82 
3 5 2 229 306 307 78 
3 5 3 209 265 281 72 
- Group 1 is the saline group, group 2 is the B-EP group, and 
group 3 is the naloxone group. 
- IW is the animals' initial weight. 
- OW is the animals' operation weight. 
- FW is the animals' final weight. 
- WG is the animals' weight gain during the experiment. 
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Group means of Body Weights and Weight Gain During the 
Experimental Period (Means + S.E) 
TIME Saline Group B-EP Group Naloxone Group 
O Min. IW (e) 211.6 ±2.6 210.3 ±2.7 210.4 ±2.7 
OW(g) 289.3 + 7.3 275.4 ±9.2 285.1 ±8.4 
FW (g) 300.9 ± 8.1 298.5 ± 7.0 298.5 ± 9.0 
WG (g) 89.3 ± 6.5 88.3 ±7.3 88.1 ± 11.6 
(N=7) (N=7) (N=7) 
60 Min. IWfe) 214.0 ±3.1 212.2 ±2.7 209.2 ± 3.0 
0W(g) 280.3 ± 3.6 286.7 ±5.6 283.3 ±4.9 
FW(g) 295.3 ±3.5 303.8 ± 5.9 300.2 ±3.1 
WG (g) 81.3 ±5.7 91.7 ±6.7 91.0 ± 12.6 
(N=6) (N=6) (N=6) 
90 Min. IWfe) 207.8 ± 2.5 211.7 ±3.1 208.8 ± 2.0 
OW (g) 291.8 ±6.3 286.2 ± 6.2 281.2 ±9.7 
FW (g) 302.5 ±5.1 299.3 ±4.1 297.5 ±6.5 
WG (g) 94.7 ± 6.6 87.7 ±4.6 88.7 ±7.5 
(N=6) (N=6) (N=6) 
120 Min. IW fe) 211.4 + 2.5 210.8 ±2.4 212.5 ±2.3 
0W(g) 270.0 ± 5.9 284.8 ± 4.4 290.7 ± 5.5 
FW (g) 283.8 ± 5.5 307.7 ± 3.6 306.0 ± 7.5 
WG (g) 72.4 ±6.9 96.8 ±5.1 93.5 ±6.3 
(N=7) (N=6) (N=6) 
(IW is initia weight, OW is operation weight, FW is final weight, 
WG is weight gain) 
Summary Statistics of Animals Initial Weight (IW) 
Source DF SS MS F Pr > F 
Treatment 2 15.9 7.9 0.17 0.84 
Time 3 60.7 20.2 0.43 0.72 
Treat*Time 6 118.8 19.8 0.42 0.85 
Error 64 2985.5 46.6 
Summary Statistics of Animals' Final Weight (FW) 
Source DF SS MS F Pr > F 
Treatment 2 643.6 321.8 1.29 0.28 
Time 3 17.9 5.9 0.02 0.99 
Treat*Time 6 2024.6 337.4 1.35 0.24 
Error 64 15989.8 46.6 
Summary Statistics on Animals Weight Gain (WG) 
Source DF SS MS F Pr > F 
Treatment 2 89.9 44.9 0.15 0.86 
Time 3 246.5 82.1 0.28 0.84 
Treat*Time 6 2579.7 429.9 1.44 0.21 
Error 64 22022.8 298.5 
